



Edison Healthcare Insight

October 2016

Published by Edison Investment Research

Lala Gregorek


Lala joined Edison's healthcare team in January 2010 from Canaccord Adams, where the focus of her coverage as a life sciences analyst was on UK and European biotech stocks. Before graduating with an M.Phil in bioscience enterprise from Cambridge University, she worked in risk management as a credit analyst covering European financial institutions and hedge funds at Dresdner Kleinwort and Lehman Brothers.

Maxim Jacobs


Max joined Edison's healthcare team in December 2014. Prior to this he worked as a senior analyst at Guidepoint Global. Max has also previously worked as a senior analyst at Ridgemark Capital, a sector head at Broadfin Capital and as a senior analyst at Mehta Partners. He is a CFA charter holder.

Pooya Hemami


Pooya is a licensed optometrist with over five years of experience in life sciences equity research. Prior to joining Edison, he covered the Canadian healthcare sector as a research analyst at Desjardins Capital Markets. He holds a doctor of optometry degree from the University of Montreal, and an MBA (finance concentration) from McGill University. He received his CFA charter in 2011.

Dr John Savin


John is an analyst working on biotech, pharma, medical device and diagnostics companies. As founder CEO of Physiomics, he devised the strategy, raised funds and took the company to AIM in 2004. At Greig Middleton, John was director in charge of the pharma and biotech analyst team and worked with corporate finance on fund-raising, IPOs and corporate restructuring. He has an industry background in sales and marketing with GE Healthcare and AstraZeneca and is a co-author on a number of scientific publications.

Juan Pedro Serrate


Juan joined Edison's Healthcare team in April 2016. A veterinarian by training, he has held business positions in the healthcare sector over the past 12 years. Juan has collaborated with independent equity research firms, specialising in fundamental analysis and valuations. For more than six years, he co-managed a seed capital fund in Spain that invested in biotech start-ups and projects. Earlier in his career, he was a research fellow at the Yale University School of Medicine. He has a Master's degree in biotechnology, as well as an MBA from IESE Business School.

Dr Dennis Hulme


Dennis joined Edison in December 2014. Prior to this he worked as an analyst at BBY Stockbrokers and as a research scientist at CSIRO. Dennis was ranked number two healthcare stock picker in the 2010 StarMine Analyst Awards and has a PhD in veterinary sciences.

Dr Linda Pomeroy


Linda joined Edison in early 2016. She has co-founded an orthopaedic company, worked for a number of years as a consultant on various NHS projects, and previously worked at Numis Securities as a life sciences analyst. Linda has a PhD from Imperial College Business School and an MPhil in bioscience enterprise from the University of Cambridge.

Susie Jana


Susie joined the team in September 2015 and has 16 years' experience in the healthcare sector. She is a qualified medical doctor, having studied medicine at UCL. She also holds an intercalated BSc in psychology. After a few years working as a junior doctor in the NHS, Susie joined the investment banking industry for six years on the sell-side covering biotechnology stocks, then mid- to large-cap pharmaceuticals at Société Générale. Most recently she worked as a buy-side analyst, covering European biotech, pharma and medtech stocks at F&C Investments for five years.

Jonas Peculis


Jonas joined Edison in November 2015. He is a qualified medical doctor with several years of clinical practice. He then moved into equity research as a healthcare analyst at Nornie Securities, focused on Norwegian companies, and received two StarMine awards for stock picking in 2013. Most recently, he worked for a London-based life sciences venture capital company before completing his MBA degree.

Daniel Wilkinson


Daniel joined Edison's Healthcare team in January 2016. He spent four years at Imperial College London, where he undertook both a Master's in Chemical Biology of Health & Disease and a PhD in Biosensors and Biotechnology in Diabetes. Before this he worked at eTect, a spin-out company from the University of Leeds that was focused on biosensor technology. He is currently studying for the Investment Management Certificate (IMC).

Dr Nathaniel Calloway


Nathaniel Calloway joined the healthcare team in December 2015. Before Edison, he performed healthcare investment research for a fund at Bishop Rosen and for Wainscott Capital Partners. Prior to his role as an analyst he performed molecular neuroscience research at Cornell Medical School and holds a PhD in chemistry from Cornell. He has published eight scientific papers on topics ranging from physical chemistry to immunology, and he has been recognised as an American Heart Association fellow and an American Chemical Society Medicinal Chemistry fellow.

Contents

Company profiles	3
Company coverage	39

Prices at 14 October 2016

Published 20 October 2016

Welcome to the October edition of the Edison Healthcare Insight. In this edition we have profiled 71 of our healthcare companies under coverage.

Readers wishing more detail should visit our website, where reports are freely available for download (www.edisongroup.com). All profit and earnings figures shown are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to close to 500 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison is a registered investment adviser regulated by the state of New York.

We welcome any [comments/suggestions](#) our readers may have.

Lala Gregorek & Maxim Jacobs

Healthcare Research

Company profiles

Prices at 14 October

US\$/£ exchange rate: 0.7823

€/£ exchange rate: 0.8745

C\$/£ exchange rate: 0.5932

A\$/£ exchange rate: 0.5945

NZ\$/£ exchange rate: 0.5651

SEK/£ exchange rate: 0.0908

DKK/£ exchange rate: 0.1174

NOK/£ exchange rate: 0.0962

JPY/£ exchange rate: 0.0077

NIS/£ exchange rate: 0.2150

CHF/£ exchange rate: 0.8010

Sector: Pharma & healthcare

Price: €2.46
Market cap: €47m
Market: FRA

Share price graph (€)

Company description

4SC is a Munich-based cancer R&D company. Epigenetic compound resminostat (HDAC inhibitor) is the lead candidate for CTCL (Phase II planned Q416), partnered with Yakult Honsha and Menarini. 4SC is partnered with Link Health for a Phase I oncology asset.

Price performance

%	1m	3m	12m
Actual	14.4	5.9	(0.2)
Relative*	10.6	0.3	(5.2)

* % Relative to local index

Analyst

Dr Linda Pomeroy

4SC (VSC)

INVESTMENT SUMMARY

4SC is focused on initiating a potentially pivotal 150-patient Phase II study with epigenetic compound resminostat (HDAC inhibitor) for cutaneous T-cell lymphoma (CTCL). The trial is due to start Q416, with initial data expected by end-2018. Resminostat has been licensed to Yakult Honsha (Japan) and Menarini (rest of Asia-Pacific). Recently announced positive Phase II results from a more detailed analysis of the HCC Yakult trial data, which could lead to further clinical development. Also, recently announced appointment of a new CEO and sale of its immunology portfolio streamlining the focus on its core business. Other positives include a recent partnership with Link Health in China for its oncology Eg5 inhibitor, 4SC-205, promising preclinical data for its epigenetic HDAC/LSD1 inhibitor (4SC-202) and promising preclinical data indicating resminostat could offer therapeutic benefit in combination with cancer immunotherapies. 4SC held €13.8m in cash (gross) at Q216, following a €29m equity issue (7.25m shares at €4.00) in July 2015.


INDUSTRY OUTLOOK

Resminostat could become the first HDAC inhibitor to gain EU approval for CTCL (vs four HDACs approved in the US). CTCL has been validated as a target indication for HDACs, with vorinostat (Merck & Co) and romidepsin (Celgene) FDA-approved on Phase II data.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2013	N/A	N/A	N/A	N/A	N/A	N/A
2014	7.1	(8.3)	(8.8)	(87.62)	N/A	N/A
2015e	3.3	(7.9)	(8.4)	(58.58)	N/A	N/A
2016e	3.8	(14.7)	(14.8)	(77.88)	N/A	N/A

Sector: Pharma & healthcare

Price: 42.0p
Market cap: £58m
Market: AIM

Share price graph (p)

Company description

Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

Price performance

%	1m	3m	12m
Actual	(7.7)	2.4	(36.8)
Relative*	(10.9)	(2.4)	(42.2)

* % Relative to local index

Analyst

Dr Linda Pomeroy

Abzena (ABZA)

INVESTMENT SUMMARY

Abzena offers fully integrated research and manufacturing services/technologies that enable its customers to develop safer and more effective biological products. This includes immunogenicity assessment, protein/antibody engineering, bioconjugation, biomanufacturing (PacificGMP) and chemistry/conjugation (TCRS). Fee-for-services provides stable revenues today (FY16 £9.9m), while successful commercialisation of products created using Abzena's technologies offers the prospect of substantial future revenues (small % royalties); 12 such products are now in the clinic, eg Gilead's GS-5745 (Phase III for gastric cancer), simtuzumab (Phase II for NASH and PSC) and Roche's SDP015. Also, ADC linker technology (ThioBridge) has recently been validated by a licensing deal with Halozyme for up to three such ADC products. PacificGMP (£5.5m) and TCRS (£10m) acquisitions enable a fully integrated offering which has created a US wide operating presence and cross selling opportunities across the expanded group.


INDUSTRY OUTLOOK

The biological services industry is highly competitive but Abzena's deepening portfolio of technologies and services is compelling, while its ADC technology offers safety and efficacy advantages over competitors.

Y/E Mar	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	5.7	(4.5)	(4.7)	(5.89)	N/A	N/A
2016	9.9	(7.0)	(7.5)	(6.00)	N/A	N/A
2017e	19.1	(5.4)	(6.8)	(4.32)	N/A	N/A
2018e	25.0	(2.9)	(4.2)	(2.63)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$7.04
Market cap: US\$962m
Market: NASDAQ

Share price graph (US\$)

Company description

Achillion is engaged in the discovery and development of treatments for chronic HCV and progressing compounds from its research platform in its novel factor D programme. It is collaborating with J&J to develop and commercialise its HCV franchise, including a triple-regimen treatment, which is potentially best in class.

Price performance

%	1m	3m	12m
Actual	(12.8)	(19.9)	(6.5)
Relative*	(12.8)	(18.9)	(11.2)

* % Relative to local index

Analyst

Maxim Jacobs

Achillion Pharmaceuticals (ACHN)

INVESTMENT SUMMARY

Achillion is developing an oral, once-a-day, single pill treatment for HCV more competitive than leader Harvoni. The company recently reported a 100% SVR rate in patients who received just 6-8 weeks of therapy in a Phase IIa study evaluating the combination of AL-335, Odalasvir (ACH-3102), and Simeprevir in genotype 1 HCV. Achillion is well funded to progress its oral factor-D programme in rare diseases, such as PNH and C3 Glomerulopathy, as well as in larger market opportunities including dry AMD. Phase I results with its factor-D inhibitor candidate, ACH-4471, were presented at the EHA meeting in June. Interim Phase II results in PNH patients are expected by year end.


INDUSTRY OUTLOOK

More than 150m people are infected with HCV worldwide. Treatment has been transformed in recent years by the approval of Sovaldi (sofosbuvir) and Gilead's combination product; recent pressure from key healthcare groups has led to a drop in HCV prices.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(61.7)	(61.7)	(62.8)	N/A	N/A
2015	66.1	(4.3)	(3.9)	(3.1)	N/A	199.0
2016e	0.0	(76.1)	(73.3)	(53.5)	N/A	N/A
2017e	0.0	(78.3)	(77.1)	(53.6)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.13
Market cap: US\$63m
Market: NYSE MKT

Share price graph (US\$)

Company description

Actinium Pharmaceuticals develops drugs for the treatment of various cancers. Actimab-A is in Phase I/II clinical trials for AML. Iomab-B is used for myeloconditioning for hematopoietic stem cell transplantation.

Price performance

%	1m	3m	12m
Actual	(32.7)	(32.7)	(50.4)
Relative*	(32.8)	(31.9)	(52.9)

* % Relative to local index

Analyst

Maxim Jacobs

Actinium Pharmaceuticals (ATNM)

INVESTMENT SUMMARY

Actinium Pharmaceuticals is actively developing its portfolio of radio-labelled antibodies to treat various cancers. Its lead product, Iomab-B, is in Phase III for use as a conditioning agent before hematopoietic stem cell therapy (HSCT, bone marrow transplantation) in refractory/relapsing acute myeloid leukaemia (AML). Actimab-A has completed the Phase I element of a Phase I/II trial in older patients with newly diagnosed AML and recently initiated the Phase II portion. Our forecasts are under review.

INDUSTRY OUTLOOK

Actinium Pharmaceuticals' targeted radiation therapies (both alpha- and beta-particle based) offer the potential of highly selective tumour cell killing with low damage to the surrounding normal tissue and limited side effects. The company aims to combine the drug delivery capabilities of antibodies with the cell-killing effect of radiation.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(22.4)	(22.5)	(90.2)	N/A	N/A
2015	0.0	(24.8)	(24.8)	(54.2)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.38
Market cap: A\$51m
Market: ASX

Share price graph (A\$)

Company description

Adherium is a digital health company developing technologies that address suboptimal medication use and remote patient management in chronic diseases. Clinical evidence shows that its Smartinhaler substantially increases adherence and reduces severe exacerbations in asthma.

Price performance

%	1m	3m	12m
Actual	2.7	(24.0)	(45.3)
Relative*	0.9	(23.4)	(47.2)

* % Relative to local index

Analyst

Dr Dennis Hulme

Adherium (ADR)

INVESTMENT SUMMARY

Adherium has developed the market-leading Smartinhaler platform that monitors usage of inhaled asthma and COPD medications and provides reminders and feedback on medication usage patterns. Independent clinical studies have shown that the Smartinhaler reminders and feedback improve patient adherence and reduce severe exacerbations in asthma patients. AstraZeneca has initiated a US clinical study that aims to confirm that the platform similarly improves adherence in COPD patients. Adherium is positioned for strong revenue growth through an existing commercial relationship with AstraZeneca and strong relationships with other pharma companies and key opinion leaders through sales for clinical trials. With A\$27m cash at 30 June 2016, Adherium has the resources to pursue an intensive growth and investment programme.


INDUSTRY OUTLOOK

Adherium has the benefit of 14 years of experience in developing and trialling Smartinhaler devices. Several competitors have entered the field more recently, but none of the competitors can match the independent clinical trials showing the efficacy of the Adherium device in improving adherence and reducing exacerbations.

Y/E Mar / Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	3.1	(1.1)	(1.3)	(1.92)	N/A	24776.0
2016	2.9	(6.5)	(6.4)	(5.39)	N/A	N/A
2017e	5.7	(11.0)	(10.5)	(6.59)	N/A	N/A
2018e	18.7	(4.6)	(4.6)	(2.73)	N/A	N/A

Sector: Pharma & healthcare

Price: NZ\$3.10
Market cap: NZ\$300m
Market: NZSX

Share price graph (NZ\$)

Company description

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company's product portfolio includes prescription and over-the-counter drugs to treat a range of conditions and a proprietary nebuliser.

Price performance

%	1m	3m	12m
Actual	3.3	(2.5)	N/A
Relative*	8.3	0.8	N/A

* % Relative to local index

Analyst

Maxim Jacobs

AFT Pharmaceuticals (AFT)

INVESTMENT SUMMARY

AFT Pharmaceuticals is a New Zealand-based speciality pharmaceutical company that currently sells 130 prescription speciality generics and OTC products through its own sales force in New Zealand, Australia and South-East Asia and has been expanding its geographic footprint. AFT has agreements in 109 countries to distribute Maxigesic, its combination acetaminophen/ibuprofen product, which is addressing a \$10.4b market. Maxigesic sales momentum has increased dramatically due to recent launches, with more to come. AFT is also developing a handheld device called SURF Nebuliser, which is able to deliver therapies intranasally, with a main focus on the \$3 billion conscious sedation market (though initially it is targeting the smaller sinusitis surgery market).

INDUSTRY OUTLOOK

AFT is a multi product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offers them a competitive advantage in a fragmented industry.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2015	56.2	(9.7)	(11.4)	(1099.7)	N/A	N/A
2016	64.0	(7.8)	(10.8)	(48.5)	N/A	N/A
2017e	77.4	(9.2)	(11.1)	(40.2)	N/A	N/A
2018e	105.4	4.3	2.5	6.4	48.4	275.1

Sector: Pharma & healthcare

Price: US\$9.20
Market cap: US\$108m
Market: NASDAQ

Share price graph (US\$)

Company description

Akari Therapeutics is a biopharmaceutical company developing Coversin, a complement system inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other immune disorders without a standard of care.

Price performance

%	1m	3m	12m
Actual	4.5	(11.5)	(50.4)
Relative*	4.5	(10.4)	(52.9)

* % Relative to local index

Analyst

Maxim Jacobs

Akari Therapeutics (AKTX)

INVESTMENT SUMMARY

Akari is biopharmaceutical company advancing the clinical development of Coversin, a complement inhibitor derived from the saliva of a species of tick. Coversin shares a mechanism of action with the \$2.59bn drug Soliris (Alexion, 2015 sales), and the company will be seeking approval for the same ultra-rare autoimmune hemolytic disorders as Soliris, as well as two other immune disorders without current treatments. The company recently announced positive interim data from a Phase Ib study where complete complement inhibition was achieved with once daily maintenance dosing. Data from a Phase II in PNH patients is expected by year end.

INDUSTRY OUTLOOK

Akari is targeting a \$2.59 billion market with their tick derived complement inhibitor. A main advantage over the competition is that Coversin can be given subcutaneously at home while competitors generally need to be given via infusion at an infusion center.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	N/A	N/A	N/A	N/A	N/A	N/A
2015	0.0	(11.3)	(49.0)	(573.33)	N/A	N/A
2016e	0.0	(22.8)	(20.9)	(170.71)	N/A	N/A
2017e	0.0	(47.3)	(48.1)	(370.69)	N/A	N/A

Sector: Pharma & healthcare

Price: 70.0p
Market cap: £52m
Market: AIM

Share price graph (p)

Company description

Angle is a pure-play specialist diagnostics company. The proprietary Parsortix cell separation platform can be used to detect and harvest very rare cells from a blood sample, including circulating tumour cells.

Price performance

%	1m	3m	12m
Actual	11.1	6.1	(14.6)
Relative*	7.2	1.0	(21.8)

* % Relative to local index

Analyst

Dr Jonas Peculis

Angle (AGL)

INVESTMENT SUMMARY

Angle's proprietary Parsortix cell separation platform can be used to detect and harvest circulating tumour cells (CTCs) from blood. FY16 results showed that the first research use sales were £361k. In May, the company announced that Cancer Research UK Manchester Institute is adopting Parsortix for routine research use, which will provide recurring sales. Recently, Angle has announced results from two clinical studies carried out by their KOL partners. The initial data show that Parsortix performs as well as or better than current standard of care in detecting early-stage prostate cancer and assessing its severity and could potentially replace invasive tissue biopsy in metastatic breast cancer. Parsortix's potential third application is for triaging women with ovarian masses before surgery, with the clinical trials ongoing in the US and Europe.


INDUSTRY OUTLOOK

The precision medicine approach is a key initiative aiming to improve treatment efficacy and outcomes by tailoring the treatment to the patient and their disease. CTCs provide information about the individual's cancer, which can be used for prognostic, diagnostic and treatment stratification purposes.

Y/E Apr	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	0.0	(3.5)	(3.6)	(7.50)	N/A	N/A
2016	0.4	(4.9)	(5.0)	(7.97)	N/A	N/A
2017e	1.1	(7.4)	(7.7)	(10.26)	N/A	N/A
2018e	3.6	(4.9)	(5.3)	(6.70)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$2.01
Market cap: US\$171m
Market: NASDAQ

Share price graph (US\$)

Company description

Athersys is a US biotech company developing MultiStem (allogeneic, bone marrow-derived stem cells). A Phase II trial with MultiStem in ischaemic stroke is complete, while further studies in AMI (Phase II) and ARDS (Phase IIa) are planned.

Price performance

%	1m	3m	12m
Actual	2.0	(10.3)	79.5
Relative*	2.0	(9.1)	70.5

* % Relative to local index

Analyst

Maxim Jacobs

Athersys (ATHX)

INVESTMENT SUMMARY

Athersys is developing MultiStem, an allogeneic, bone marrow-derived stem cell product. Results from a 140-patient Phase II study in ischaemic stroke revealed a potential benefit when dosed <36 hours post stroke (vs 3-5 hours with tPA), although the primary/secondary endpoints were not met on an intent-to-treat basis. Athersys recently signed a partnership agreement with Healios in Japan for stroke and other indications. The company has reached an agreement with both the FDA (through an SPA) and the PMDA on the design of the pivotal trials necessary for approval in those regions (a 300-pt trial in the US and a ~150-200pt. trial in Japan).

INDUSTRY OUTLOOK

MultiStem is an allogeneic (off-the-shelf) product that allows it to be used in both acute and chronic treatment settings, and holds potential to be used across a range of indications. Regenerative medicine is gaining traction and recognition by global regulators (eg accelerated approval pathway in Japan).

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	1.6	(29.3)	(28.9)	(37.26)	N/A	N/A
2015	11.9	(17.5)	(17.2)	(20.93)	N/A	N/A
2016e	16.5	(16.9)	(16.4)	(19.18)	N/A	N/A
2017e	0.0	(34.4)	(34.1)	(39.46)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.80
Market cap: US\$7m
Market: NASDAQ

Share price graph (US\$)

Company description

Based in Seattle, WA, Atossa Genetics is focused on the development of locally administered pharmaceuticals for the treatment of pre-cancer and early-stage breast cancer. Lead candidate afimoxigene topical gel is expected to start a Phase II study in 2016 in breast hyperplasia or DCIS.

Price performance

%	1m	3m	12m
Actual	(12.6)	(57.2)	(84.8)
Relative*	(12.6)	(56.6)	(85.6)

* % Relative to local index

Analyst

Pooya Hemami

Atossa Genetics (ATOS)

INVESTMENT SUMMARY

Atossa is advancing its proprietary intraductal microcatheter (IDMC), intended to selectively introduce drugs to breast ducts, potentially improving drug targeting for chemotherapy. It plans to combine its IDMC with established cancer drug fulvestrant and opened enrolment for a 30-patient Phase II study in March 2016. Atossa recently started advancing oral endoxifen, a metabolite of tamoxifen, as a potential treatment for breast cancer patients refractory to tamoxifen. Up to half of the 1.0m US women taking tamoxifen develop resistance to it (for multiple reasons, including low levels of liver enzyme CYP2D6), and have an increased risk for cancer recurrence.

INDUSTRY OUTLOOK

IDMC-fulvestrant development may hinge on future FDA guidance on whether the projects can fall under the 505(b)2 development pathway, which would reduce the breadth of clinical data needed to support a marketing application. Atossa filed endoxifen patent applications and contracted for the initial drug supply; it plans to start an endoxifen human study in 2017. Atossa raised \$2.9m in an equity offering in Q316.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	0.0	(6.9)	(7.3)	(30.5)	N/A	N/A
2015	0.0	(9.5)	(9.8)	(34.3)	N/A	N/A
2016e	0.0	(10.1)	(10.4)	(28.6)	N/A	N/A
2017e	0.0	(14.1)	(14.6)	(35.8)	N/A	N/A

Sector: Pharma & healthcare

Price: CHF73.50
Market cap: CHF868m
Market: Swiss Stock Exchange

Share price graph (CHF)

Company description

Basilea is a Swiss biopharmaceutical company focused on anti-infectives and oncology. Its lead products are Cresemba, antifungal that is approved in the US and Europe and Zevtera, an anti-MRSA broad-spectrum antibiotic, approved in Europe for pneumonia.

Price performance

%	1m	3m	12m
Actual	4.5	7.6	(30.0)
Relative*	5.2	8.8	(24.4)

* % Relative to local index

Analyst

Dr Susie Jana

Basilea Pharmaceutica (BSLN)

INVESTMENT SUMMARY

Basilea is one of the few standalone European companies focused on developing novel antimicrobial drugs. It has two approved hospital-based products: Cresemba for severe mold infections and Zevtera for bacterial infections. Zevtera should enter US phase III development in H1 2017 following discussions with FDA on PIII (seeking SPA) and the award of a BARDA (division of US Dept. of Health & Human Services Office) contract up to \$100m for its phase III development. Basilea's earlier-stage oncology pipeline focuses on drugs that target resistance to current cancer therapies. BAL101553 is being developed as a tumor checkpoint controller and recently presented final phase I/IIa data at ASCO. BAL3833, a panRAF kinase inhibitor, is in Phase I development.


INDUSTRY OUTLOOK

There is an increasing need for novel antimicrobial agents with efficacy against resistant strains of bacteria (eg MRSA), and/or improved side effect profiles. Hence the opportunities for Zevtera and Cresemba could be significant.

Y/E Dec	Revenue (CHFm)	EBITDA (CHFm)	PBT (CHFm)	EPS (fd) (CHFc)	P/E (x)	P/CF (x)
2014	42.6	(39.2)	(41.2)	(414.46)	N/A	N/A
2015	52.8	(58.9)	(61.3)	(607.22)	N/A	N/A
2016e	61.2	(46.8)	(54.1)	(496.01)	N/A	N/A
2017e	88.6	(28.7)	(35.6)	(319.87)	N/A	N/A

Sector: Pharma & healthcare

Price: 116.5p
Market cap: £38m
Market: AIM

Share price graph (p)

Company description

C4X Discovery is a UK business using its proprietary NMR-based technology to enable rational drug design, aimed at selecting safer and better drugs in a reduced timeframe. An OX1 receptor antagonist is the lead pre-clinical candidate.

Price performance

%	1m	3m	12m
Actual	13.7	(6.8)	72.6
Relative*	9.7	(11.2)	58.1

* % Relative to local index

Analyst

Dr Linda Pomeroy

C4X Discovery Holdings (C4XD)

INVESTMENT SUMMARY

C4X Discovery's (C4XD) proprietary drug discovery platform aims to become a highly efficient and productive discovery R&D engine. The Orexin programme, a selective OX1 antagonist, is the lead candidate, with Phase I anticipated by mid-2017. Recently acquired proprietary human genetic technology platform (Taxonomy3) and Molplex technologies, broadens its drug discovery capabilities to both target identification and lead generation. Also, recently announced a strategic collaboration with Evotec, building on a previous agreement. The agreement is a risk-shared multi-target programme. This is a positive development and builds on the recent recent fundraising of £5m (before expenses) as it enables outputs from its drug discovery engine and its preclinical pipeline to progress.

INDUSTRY OUTLOOK

C4XD's NMR-based technology can be used to solve the 3-D conformations of biomolecules in solution, which the company believes will enable data-driven rational design of superior drug candidates, on a significantly faster timescale than conventional techniques, which should appeal to the global pharma industry. Existing partnerships (Evotec, AstraZeneca and Takeda) and the Structural Genomics Consortium collaboration provide external validation of the technology.

Y/E Jul	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (fd) (p)	P/E (x)	P/CF (x)
2014	0.6	(1.2)	(1.3)	N/A	N/A	N/A
2015	0.3	(3.8)	(3.8)	(10.75)	N/A	N/A
2016e	0.3	(7.1)	(7.0)	(17.77)	N/A	N/A
2017e	0.2	(8.2)	(8.3)	(20.33)	N/A	N/A

Sector: Pharma & healthcare

Price: €37.71
Market cap: €224m
Market: Alternext Paris

Share price graph (€)

Company description

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Price performance

%	1m	3m	12m
Actual	(3.8)	10.5	(31.8)
Relative*	(7.0)	6.4	(29.7)

* % Relative to local index

Analyst

Pooya Hemami

Carmat (ALCAR)

INVESTMENT SUMMARY

As part of the feasibility stage of the CE-mark approval process, Carmat's bioprosthetic heart was implanted in the required four patients. A CE-mark enabling pivotal study was cleared by regulators in July 2016, and the first patient implant for this trial took place in late August 2016. The trial could be completed by 2018, potentially leading to CE-mark awarding and EU market entry in H218. In the US, Carmat's options for attaining regulatory approval include a humanitarian use device (HUD) approval or a broader pre-market approval (PMA) process, providing an addressable market of up to 50,000 US patients. Carmat raised €50m in equity in February 2016, which we estimate can finance operations into H118.


INDUSTRY OUTLOOK

The Carmat artificial heart is being developed as a permanent replacement or destination therapy (DT) for chronic heart failure or acute myocardial infarction patients, who do not have access to a human donor heart. Despite the high worldwide prevalence of heart failure (c 100,000 patients), the shortfall in donor hearts is such that only about 3,800 human heart transplants were performed in Europe and the US in 2013.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(19.4)	(20.3)	(414.0)	N/A	N/A
2015	0.0	(19.4)	(20.6)	(381.0)	N/A	N/A
2016e	0.0	(22.0)	(21.9)	(335.0)	N/A	N/A
2017e	0.0	(22.0)	(21.8)	(368.0)	N/A	N/A

Sector: Pharma & healthcare

Price: €17.50
Market cap: €163m
Market: Euronext Brussels

Share price graph (€)

Company description

Celyad is developing C-Cure, an autologous Phase III stem cell therapy for chronic ischaemic heart disease. An innovative cell cancer CAR T-cell therapy, NKG2D, is in Phase I.

Price performance

%	1m	3m	12m
Actual	(9.0)	(23.6)	(46.8)
Relative*	(11.1)	(27.4)	(49.3)

* % Relative to local index

Analyst

Dr John Savin

Celyad (CYAD)

INVESTMENT SUMMARY

The Japanese pharmaceutical company ONO is jumping a therapeutic generation by licensing Celyad's allogeneic preclinical NKR-T cancer cell therapy for Japan, Korea and Taiwan. Allogeneic NKR-T has the same action as the Phase I/II NKR-T autologous product; allogeneic versions could be mass produced and provided "off the shelf". ONO paid €11.25m cash with €270.75m possible in milestones plus royalties. NKR-T is being tested in two haematological cancers and has completed its dose ranging study. Trials in solid tumours are planned for early 2017. H116 accounts showed cash of €86m (\$97m).


INDUSTRY OUTLOOK

Celyad's Phase III CHART-1 study in cardiac regeneration missed its primary endpoint, but a clinically defined EDV subgroup with 60% of patients saw a positive outcome, p=0.015. Celyad management intends to submit a conditional marketing authorisation for European approval. Further data was shown on 28 August at the ESC meeting. The US Chart-2 trial with a new endpoint and EDV focus will run if partnered.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.1	(18.2)	(18.5)	(273.41)	N/A	N/A
2015	0.0	(28.6)	(28.4)	(326.28)	N/A	N/A
2016e	11.3	(14.5)	(14.3)	(153.56)	N/A	N/A
2017e	0.0	(57.7)	(57.7)	(619.87)	N/A	N/A

Sector: Pharma & healthcare

Price: 1138.0p
Market cap: £560m
Market: LSE

Share price graph (p)

Company description

Consort Medical is an international medical devices business. Having acquired Aesica Pharmaceuticals for £230m in 2014, it now consists of Bepak's operations (inhalation, injection and other drug delivery technologies) and Aesica's CDMO businesses.

Price performance

%	1m	3m	12m
Actual	7.0	11.0	23.2
Relative*	3.2	5.7	12.8

* % Relative to local index

Analyst

Lala Gregorek

Consort Medical (CSRT)

INVESTMENT SUMMARY

Consort Medical is a full-service contract development and manufacturing operation (CDMO) that operates across most areas of the pharmaceutical supply chain. Bepak's strength in high-margin disposable drug delivery devices is complemented by Aesica's services from drug manufacture to finished product packaging. Consort Medical capitalises on the growing trend for drug majors to outsource more of their non-core activities to specialist providers, as it addresses more of the development and manufacturing functions while also striving to build operational scale.


INDUSTRY OUTLOOK

Management has positioned Consort Medical to generate sustainable revenue and profit growth, with the latter targeted at a double-digit rate. Improvements in operating efficiencies, coupled with investment in innovation and development capabilities, has laid the foundation for establishing a broader range of contract services.

Y/E Apr	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	184.8	33.2	22.7	47.8	23.8	21.0
2016	276.9	47.6	32.3	57.6	19.8	11.9
2017e	281.5	50.1	33.5	55.8	20.4	11.6
2018e	298.7	54.3	36.3	60.5	18.8	10.8

Sector: Pharma & healthcare

Price: €6.93
Market cap: €49m
Market: Euronext Paris

Share price graph (€)

Company description

Crossject develops new therapeutic entities (supergeneric) to be administered using its proprietary, needle-free injection system, ZENEO. Crossject has seven products in its development pipeline, including products for rheumatoid arthritis, anaphylactic shock, migraine and Parkinson's.

Price performance

%	1m	3m	12m
Actual	(11.3)	(3.1)	63.4
Relative*	(14.2)	(6.6)	68.5

* % Relative to local index

Analyst

Maxim Jacobs

Crossject (ALCJ)

INVESTMENT SUMMARY

Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, ZENEO, across a variety of indications. The benefits of ZENEO include no need for needles, as well as a simple and quick (~1/10th of a second) delivery of the drug. Its first commercial product, ZENEO Methotrexate for rheumatoid arthritis, should reach the market in 2017. The next product to reach the market will likely be ZENEO Sumatriptan for the acute treatment of migraine, which is expected to be commercialised in H118. Crossject also recently announced that their program dubbed L15 is actually a needle free version of Hydrocortisone for acute adrenal insufficiency. Launch is expected in H118.

INDUSTRY OUTLOOK

Traditional injections have multiple issues with them which inhibit patient acceptance. These often include: a multi-step injection process, difficulty in performing the injection correctly and convenience.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	1.7	(4.1)	(5.3)	(65.64)	N/A	N/A
2015	2.4	(5.5)	(6.7)	(85.33)	N/A	N/A
2016e	3.1	(5.0)	(5.4)	(61.57)	N/A	N/A
2017e	3.0	(8.5)	(9.7)	(104.51)	N/A	N/A

Sector: Pharma & healthcare

Price: 9.2p
Market cap: £25m
Market: AIM

Share price graph (p)

Company description

e-Therapeutics is a UK-based drug discovery company that has developed a proprietary network pharmacology discovery platform. Its focus is now on commercialisation: securing partners for its discovery and development projects.

Price performance

%	1m	3m	12m
Actual	(14.0)	(22.1)	(66.4)
Relative*	(17.0)	(25.8)	(69.2)

* % Relative to local index

Analyst

Lala Gregorek

e-Therapeutics (ETX)

INVESTMENT SUMMARY

e-Therapeutics is a leader in network pharmacology, an innovative approach to drug discovery. The resignation of founder CEO Professor Malcolm Young has prompted organisational changes. Chairman Iain Ross becomes executive chairman, taking responsibility for corporate and commercial discussions. Other changes include the appointment of CFO Steve Medicott as interim COO, and non-executive director, Professor Trevor Jones, becoming responsible for oversight of the scientific team and a newly initiated comprehensive project review. As e-Therapeutics seeks to transition to commercialisation under new leadership, management attention is focused on finding a new CEO to continue to develop the business and secure partnerships. Deals should validate the platform, as well as fund future discovery work, identifying the next wave of lead candidates. Cash and deposits were £19.9m as of 31st July 2016.

INDUSTRY OUTLOOK

Network pharmacology could potentially revolutionise drug discovery and shorten the path to market by minimising technical risks and drug development costs. e-Therapeutics is well positioned, with limited direct competition and growing industry interest in systems biology-based multi-target approaches to drug discovery.

Y/E Jan	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	0.0	(10.0)	(9.7)	(2.9)	N/A	N/A
2016	0.0	(11.3)	(11.1)	(3.2)	N/A	N/A
2017e	0.0	(11.8)	(11.6)	(3.2)	N/A	N/A
2018e	0.0	(8.9)	(8.9)	(2.3)	N/A	N/A

Sector: Pharma & healthcare

Price: €5.07
Market cap: €674m
Market: FRA

Share price graph (€)

Company description

Evotec is a drug discovery business that provides outsourcing solutions to pharmaceutical companies, including Bayer, Boehringer Ingelheim, Janssen and Roche. It has operations in Germany, France, the UK and the US.

Price performance

%	1m	3m	12m
Actual	11.2	30.0	28.2
Relative*	7.4	23.1	21.8

* % Relative to local index

Analyst

Dr Jonas Peciulis

Evotec (EVT)

INVESTMENT SUMMARY

Evotec delivered better than expected H116 results with 37% total and 35% base revenue (excluding milestones, upfronts and licences) increases year-on-year. Double-digit base revenue growth guidance of >15% was reiterated, while adjusted EBITDA is now seen to more than double, underpinned by the continued growth of the company's core drug discovery services business. Recently Evotec contributed \$6m to Carrick Therapeutics' \$95m funding round co-led by ARCH Venture Partners and Woodford Investment Management with another four VCs. This was a second equity investment for Evotec after it had spun out Topas Therapeutics in March and shows the company's interest in finding funding solutions for promising pre-clinical assets developed in-house or by other parties. Evotec also reached milestones in its partnership with Bayer, which is now progressing into Phase I with a new, first-in-class treatment for endometriosis, one of the largest unmet needs in women's health area, in our view.


INDUSTRY OUTLOOK

Evotec is a healthcare company that provides high-quality drug discovery services to the pharmaceutical industry and has collaborations with academic institutions to create novel drug discovery programmes.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	89.5	7.7	(0.7)	(1.96)	N/A	N/A
2015	127.7	8.7	1.2	(1.11)	N/A	40.9
2016e	157.4	26.6	15.0	6.68	75.9	96.2
2017e	177.4	30.5	21.2	11.31	44.8	22.4

Sector: Pharma & healthcare

Price: 62.5p
Market cap: £12m
Market: AIM

Share price graph (p)

Company description

Genedrive has a profitable contract services business and an emerging clinical biomarker technology.

Price performance

%	1m	3m	12m
Actual	0.0	(26.5)	(62.1)
Relative*	(3.5)	(30.0)	(65.3)

* % Relative to local index

Analyst

Dr John Savin

Genedrive (GDR)

INVESTMENT SUMMARY

Genedrive plc, previously Epistem, sells via its sole Indian distributor, Xcelris Labs, the Genedrive unit and molecular tuberculosis diagnostic test targeting 5,000 private Indian laboratories. The Contract Research business is being divested. It made £2.01m sales in FY2016; profit of £51k. The Pharmacogenomics business had sales of £1.15; loss of £175k. The Genedrive division had revenues of £1.92m from a US defense research contract; loss of £2.88m. Administration was £2.42m. Genedrive made an overall loss of £5.43m. Cash on 30 June 2016 was £1.11m before a net £6.05m placing in July. Our forecasts are under review.


INDUSTRY OUTLOOK

Genedrive believes its Genedrive DNA-based point-of-care diagnostic system will enable accurate low cost testing for TB. Sales development has been minimal since the April 2016 launch with no new orders gained but an improved sales strategy and some technical improvements are being developed. A hepatitis C test also targeted at the Indian market is in late development.

Y/E Jun	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2014	5.8	(1.6)	(2.3)	(17.4)	N/A	N/A
2015	4.5	(3.7)	(3.4)	(30.2)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €1.52
Market cap: €24m
Market: Euronext Paris

Share price graph (€)

Company description

Gentical is developing a therapeutic vaccine, GTL001, to treat early-stage HPV 16 and 18 infections. The Phase II trial missed the primary endpoint but more data is due in mid 2016. A multivalent therapeutic vaccine, GTL002 is in preclinical.

Price performance

%	1m	3m	12m
Actual	(23.6)	(12.1)	(75.8)
Relative*	(26.1)	(15.3)	(75.0)

* % Relative to local index

Analyst

Juan Pedro Serrate

Gentical (GTCL)

INVESTMENT SUMMARY

Gentical announced 18-month data from the Phase II trial of the GTL001 vaccine to treat early-stage human papillomavirus 16 and 18 infections (HPV16/18). In this update, GTL001 showed no statistically significant difference in any subgroup. Safety remains positive. Gentical will present 24-month data in Q117, which will include the full data set and inform next steps. Additionally, the company has engaged corporate specialist Eumedix to advise on business development activities. Cash is €14.7m in June 2016, sufficient until 2018.


INDUSTRY OUTLOOK

As GTL001 is under review, 24 month data will be useful to assess the future of the product. Lessons learnt from the fully completed trial could allow a partnership to assess GTL001 in a new Phase II trial focused on a specific subgroup of patients that have shown a sufficiently robust signal. A partnership could also be focused on preparing the next-generation candidate GTL002 for Phase I.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(10.9)	(10.8)	(78.1)	N/A	N/A
2015	0.2	(11.4)	(11.2)	(72.1)	N/A	N/A
2016e	0.0	(8.8)	(8.7)	(55.8)	N/A	N/A
2017e	0.0	(8.3)	(8.3)	(53.4)	N/A	N/A

Sector: Pharma & healthcare

Price: 853.0p
Market cap: £2577m
Market: AIM, NASDAQ

Share price graph (p)

Company description

GW is a UK-based speciality pharma company developing cannabinoid medicines. Lead pipeline candidate Epidiolex is undergoing Phase III trials for childhood epilepsy. Sativex is marketed by partners in a number of EU countries for MS spasticity.

Price performance

%	1m	3m	12m
Actual	26.4	48.9	79.3
Relative*	21.9	41.8	64.2

* % Relative to local index

Analyst

Maxim Jacobs

GW Pharmaceuticals (GWP)

INVESTMENT SUMMARY

GW Pharmaceuticals (GW) is developing an extensive cannabinoid portfolio with potential to treat a broad range of diseases. The lead pipeline asset is Epidiolex, now undergoing a multiple Phase III clinical study program for refractory childhood epilepsies. Initial top-line Phase III data from their one trial in Dravet syndrome and two trials in Lennox-Gastaut syndrome (LGS) were all statistically significant. We expect an NDA filing for both Dravet and LGS early next year. They have also recently commenced a Phase III in Tuberous Sclerosis Complex (TSC) and expect to commence a Phase III in infantile spasms in Q416.


INDUSTRY OUTLOOK

GW is the leading player in cannabinoid medicines. Cannabinoids are diverse chemical compounds that GW extracts from cannabis plant varieties (chemotypes) it has bred. Epidiolex has the potential to treat a broad range of treatment-refractory epilepsy conditions, while the portfolio extends to other orphan indications such as TSC epilepsy and NHIE.

Y/E Sep	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2014	30.0	(17.0)	(18.3)	(6.4)	N/A	N/A
2015	28.5	(54.6)	(55.8)	(17.6)	N/A	N/A
2016e	8.8	(94.4)	(95.2)	(29.9)	N/A	N/A
2017e	11.4	(84.0)	(85.0)	(25.6)	N/A	N/A

Sector: Pharma & healthcare

Price: 1822.5p
Market cap: £1105m
Market: AIM, NASDAQ

Share price graph (p)

Company description

Hutchison China MediTech (HCM) is an innovative China-based biopharma company targeting the global market for novel, highly selective oral oncology and immunology drugs. Its established China Healthcare business is growing ahead of the market. HCM is the healthcare arm of CK Hutchison (c 40% listed on AIM and NASDAQ).

Price performance

%	1m	3m	12m
Actual	(0.3)	(5.3)	(15.1)
Relative*	(3.8)	(9.8)	(22.3)

* % Relative to local index

Analyst

Dr Susie Jana

Hutchison China MediTech (HCM)

INVESTMENT SUMMARY

HCM has built a substantial pipeline of potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, some of which are in development with strategic partners. We expect progress of the mid- to late-stage pipeline during 2016-17 (including US and China regulatory filings) to catapult the company into the international spotlight. The pipeline is progressing well, material clinical results are expected during the coming year. The company has successfully raised net proceeds of approximately US\$95.9m via a secondary listing of ADRs on the NASDAQ exchange. PBT excludes the earnings contributions from JVs, which in 2015 reported at \$22.57m (as equity in investees, net of tax). Cash as of June 30th 2016 is \$197.5m. The amended AstraZeneca agreement announced at the interim results is currently not reflected in our forecasts.


INDUSTRY OUTLOOK

HCM's profitable Chinese healthcare business continues to benefit from the fast-growing domestic market, while the clinical, regulatory and technological environments are highly conducive to novel drug development. In the longer term, if the oncology and immunology pipeline comes to fruition, HCM has the potential to become a global oncology and immunology player.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	87.3	(17.0)	(20.0)	(17.8)	N/A	146.6
2015	178.2	(7.8)	(10.5)	14.6	159.6	N/A
2016e	180.4	(43.3)	(48.1)	(0.5)	N/A	N/A
2017e	226.0	(20.5)	(26.7)	6.0	388.3	N/A

Sector: Pharma & healthcare

Price: €0.84
Market cap: €30m
Market: Alternext Paris

Share price graph (€)

Company description

Hybrigenics is a French biotech company. It provides protein-protein and small molecule analysis services and is conducting anti-cancer studies on lead drug inecalcitol, primarily in adult leukaemias.

Price performance

%	1m	3m	12m
Actual	(6.7)	(5.6)	(34.4)
Relative*	(9.7)	(9.1)	(32.3)

* % Relative to local index

Analyst

Juan Pedro Serrate

Hybrigenics (ALHYG)

INVESTMENT SUMMARY

Hybrigenics has adopted a development strategy with vitamin D3 derivative inecalcitol, first focusing on adult haematological cancers. In addition to chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML), Hybrigenics is prioritising acute myeloid leukaemia (AML) given inecalcitol's orphan status in the US and Europe and the scarcity of treatment options in this aggressive and difficult to treat leukaemia. An international Phase II study in AML has started recruiting patients in France in September 2016. Interim Phase II data are expected in 2016 in CML. Inecalcitol is supported by strong anti-proliferative potency and excellent safety profile demonstrated in the 2014 CLL study. The investment case rests on inecalcitol's potential to enhance rather than replace approved therapies, particularly in view of the weakened general health of older leukaemia patients who are unable to tolerate therapies with harmful side effects. Our peak sales estimate is US\$769m.

INDUSTRY OUTLOOK

Inecalcitol faces competition from existing drugs and those in development. However, a good safety profile could give it an advantage. Preclinical models show that it has additional potential in breast cancer. Hybrigenics has a cash-generative subsidiary in protein research and genomics services.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	6.8	(2.1)	(2.2)	(8.5)	N/A	N/A
2015	6.5	(3.6)	(3.6)	(10.6)	N/A	N/A
2016e	6.1	(6.0)	(5.9)	(16.6)	N/A	N/A
2017e	6.3	(6.4)	(6.5)	(18.1)	N/A	N/A

Sector: Pharma & healthcare

Price: 406.8p
Market cap: £656m
Market: LSE

Share price graph (p)

Company description

Imperial Innovations is a technology transfer, incubation and venture investment company. It invests in ventures from Imperial College London, Cambridge and Oxford Universities and UCL. The majority of its investments are bio/med tech.

Price performance

%	1m	3m	12m
Actual	(11.1)	(7.3)	(19.5)
Relative*	(14.2)	(11.7)	(26.2)

* % Relative to local index

Analyst

Lala Gregorek

Imperial Innovations (IVO)

INVESTMENT SUMMARY

Imperial Innovations (IVO) has c £198.3m available for portfolio investment consisting end-July cash of £148.3m and a £50m EIB loan facility. IVO invested £66.9m across 33 portfolio companies in FY16 (FY15: £60.8m across 30), including the addition of seven accelerated growth companies. Net fair value loss for full year was £56.2m which consisted of a quoted £66.9m net fair value loss and an unquoted £10.7m net fair value gain. The quoted loss can be attributed mainly to Circassia (£54.8 of £63.1m) who posted negative phase III results for its cat allergy in June. The unquoted portfolio continues to progress well and shows growth though fair value gains and investment activity.


INDUSTRY OUTLOOK

The investment case rests on the real value of the portfolio and the success of investments in maturing companies. There is potential for significant value creation if 'exits' (IPOs/M&A/license deals) are achieved at valuations in excess of typically modest carrying values, which justifies IVO's current share price premium (net portfolio value of £335.1m as of 31 July 2016, vs £327.2m at 31 July 2015).

Y/E Jul	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	5.1	(8.2)	(7.4)	(5.4)	N/A	N/A
2016	4.3	(9.8)	(9.8)	(6.7)	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: NIS20.02
Market cap: NIS229m
Market: TASE

Share price graph (NIS)

Company description

Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson's in Phase III and AP-ZP for insomnia in Phase II.

Price performance

%	1m	3m	12m
Actual	(12.1)	17.1	(7.7)
Relative*	(10.8)	19.0	(0.3)

* % Relative to local index

Analyst

Maxim Jacobs

Intec Pharma (NTEC)

INVESTMENT SUMMARY

Intec Pharma is a drug delivery company that has developed a novel drug delivery device termed the accordion pill (AP), a folded, multilayer membrane packaged into a normal capsule, which expands to a sheet within the stomach to many times its original size. This property causes the pill to be retained in the stomach for up to 12 hours. This is ideal for drugs with local activity in the stomach or upper digestive tract or with poor solubility. The company currently has two disclosed development programmes: AP-CDLD, a controlled release formulation of carbidopa and levodopa for Parkinson's in Phase III; and AP-ZP, a controlled release formulation of zaleplon for insomnia ready to enter Phase III though awaiting a strategic partner before doing so.


INDUSTRY OUTLOOK

Parkinson's disease is a neurodegenerative disease in which the dopamine secreting neurons in the brain are lost, leading to severe motor defects and cognitive impairment. Approximately one million people in the US have Parkinson's.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2014	0.0	(22.8)	(20.4)	(4.22)	N/A	N/A
2015	0.0	(32.4)	(27.9)	(3.58)	N/A	N/A
2016e	0.0	(54.9)	(50.6)	(4.31)	N/A	N/A
2017e	0.0	(55.4)	(51.6)	(4.18)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.84
Market cap: US\$7m
Market: OTCQX

Share price graph (US\$)

Company description

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells (hpSCs). Its lead candidate is a cell therapy treatment for Parkinson's disease.

Price performance

%	1m	3m	12m
Actual	(3.4)	5.4	(53.2)
Relative*	(3.4)	6.8	(55.5)

* % Relative to local index

Analyst

Maxim Jacobs

International Stem Cell (ISCO)

INVESTMENT SUMMARY

International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson's disease (PD), with preliminary data expected before the end of the year. Preclinical safety data was recently published in Nature. With its hpSC technology, ISCO has created 15 stem cell lines, each of which is a different HLA type. From this, it creates different cell types such as liver cells, neural cells and three-dimensional eye structures. In addition, ISCO sells skincare and biomedical supplies to the market, generating \$8m in sales and \$1.7m in underlying operating profit in 2015.


INDUSTRY OUTLOOK

ISCO's technology platform is based on human parthenogenetic stem cells (hpSCs). Parthenogenetic stem cells are created from unfertilized human eggs (oocytes) chemically activated to make the cells pluripotent. As hpSCs express fewer parental histocompatibility antigens, they reduce the risk of immune rejection.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	7.0	(9.1)	(8.7)	(970.82)	N/A	N/A
2015	7.6	(5.0)	(4.6)	(129.29)	N/A	N/A
2016e	8.2	(5.5)	(5.5)	(173.36)	N/A	N/A
2017e	9.0	(5.2)	(5.8)	(182.56)	N/A	N/A

Sector: Pharma & healthcare

Price: €10.67
Market cap: €149m
Market Euronext Amsterdam

Share price graph (€)

Company description

Kiadis Pharma is a biotech company focused on cell-based immunotherapies to overcome complications associated with stem cell transplants in blood diseases. ATIR101 for leukaemia is in Phase II and will file for EU approval in Q117. ATIR201 (thalassemia) is in preclinical; a Phase I/II will start in H216.

Price performance

%	1m	3m	12m
Actual	(4.7)	(9.3)	(5.9)
Relative*	(7.7)	(10.2)	(7.0)

* % Relative to local index

Analyst

Juan Pedro Serrate

Kiadis Pharma (KDS)

INVESTMENT SUMMARY

Kiadis Pharma is developing T cell-based therapies to address the issues associated with haematopoietic stem cell transplantation (HSCT). The company is leveraging its Theralux technology to develop ATIR101 and ATIR201 as adjunct therapies to HSCT in leukaemia and thalassemia, respectively. On the back of Phase II data, Kiadis is aiming for accelerated filing of ATIR101 with the European Medicines Agency (EMA) in Q117. A Phase III trial will start in H216. ATIR201 will start a Phase I/II trial in H216. Cash at end June 2016 was €23.7m, sufficient to fund operations until early 2018. We value the company at €327.3m or €27.1/share.

INDUSTRY OUTLOOK

Kiadis's Theralux platform allows the infusion of lymphocytes from a partially matching (haploidentical) family member to the donor as it eliminates cells that could react against the host's immune cells and cause complications such as Graft vs Host Disease (GVHD).

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(6.0)	(7.2)	(7.5)	N/A	N/A
2015	0.0	(15.9)	(17.4)	(13.6)	N/A	N/A
2016e	0.0	(8.6)	(10.0)	(8.3)	N/A	N/A
2017e	0.0	(11.9)	(13.5)	(11.2)	N/A	N/A

Sector: Pharma & healthcare

Price: €4.25
Market cap: €109m
Market FRA

Share price graph (€)

Company description

MagForce has a European approved nanotechnology-based therapy to treat brain cancer. Nanoparticles are injected into the tumour and activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Price performance

%	1m	3m	12m
Actual	(7.6)	(12.4)	(19.9)
Relative*	(10.7)	(17.1)	(23.8)

* % Relative to local index

Analyst

Dr Susie Jana

MagForce (MF6)

INVESTMENT SUMMARY

MagForce continues to drive forward its strategy to increase uptake of its NanoTherm therapy for cancer. NanoTherm is approved in Europe for brain cancer and commercial patients are being treated in Germany. Six NanoActivators are currently installed in Germany. In the US, an IDE for prostate cancer is filed and management is working with FDA to advance the IDE approval. The first clinical treatment site is operational (other sites are in development) and will be used in the short-term to provide the required pre-clinical study data. Note: Our financial forecasts have not been updated post publication of FY14 and FY15 results.


INDUSTRY OUTLOOK

MagForce's NanoTherm therapy has been designed to directly affect tumours from within, while sparing surrounding healthy tissue. Magnetic nanoparticles are directly injected into a tumour and are then heated in the presence of an external magnetic field generated by specialist equipment (NanoActivator). This can destroy or sensitise the tumour for additional treatment.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(8.0)	(7.9)	(32.8)	N/A	N/A
2015	2.6	(4.4)	(4.5)	(18.0)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €10.01
Market cap: €202m
Market: FRA

Share price graph (€)

Company description

Medigene is a German biotech company with a core business in cancer immunotherapy. Dendritic cell (DC) vaccines are in Phase I/II clinical studies, while a T-cell receptor (TCR) candidate should enter the clinic in 2016.

Price performance

%	1m	3m	12m
Actual	46.6	36.2	68.8
Relative*	41.7	28.9	60.5

* % Relative to local index

Analyst

Dr Linda Pomeroy

Medigene (MDG1)

INVESTMENT SUMMARY

Medigene is focused on the rapid development of its cancer immunotherapy technology platforms: dendritic cell (DC) cancer vaccines, adoptive T-cell therapy (TCR) and T-cell specific antibodies (TAB). Phase I/II studies are underway with DC vaccines for prostate cancer and acute myeloid leukaemia (investigator-sponsored) and acute myeloid leukaemia (Medigene). For TCRs, Medigene plans to start up to three clinical trials; the first in 2017 (investigator-led) and others in 2017 and 2018. Recent important progress includes an alliance with bluebird bio, a prominent T-cell immunology company, to utilise its TCR technology platform to identify four therapeutic candidates against four targets. This is positive as it validates its TCR technology and offers potential upside from any development. Medigene held €48.7m in cash at Q216, following a €46m equity issue (5.6m shares at €8.30) in July 2015.

INDUSTRY OUTLOOK

Cancer immunotherapy is attracting huge biotech investor interest. Medigene's DC vaccine technology is a new generation, with multiple potential efficacy and manufacturing benefits over the forerunners, eg Provenge. The TCR programme has similarities to CAR-T products, but with potentially significant efficacy and safety advantages.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	13.8	(2.0)	(5.3)	(42.0)	N/A	N/A
2015	6.8	(9.4)	(12.8)	(74.0)	N/A	N/A
2016e	7.1	(11.1)	(13.1)	(66.0)	N/A	N/A
2017e	7.3	(12.1)	(13.5)	(67.0)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$1.12
Market cap: A\$427m
Market: ASX

Share price graph (A\$)

Company description

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas.

Price performance

%	1m	3m	12m
Actual	(4.7)	(2.2)	(67.2)
Relative*	(6.3)	(1.3)	(68.3)

* % Relative to local index

Analyst

Dr Dennis Hulme

Mesoblast (MSB)

INVESTMENT SUMMARY

Mesoblast cut its cash burn by 15% in FY16 to US\$90m, and guided for a further ~25% reduction in FY17, which will give it headroom to fund the Phase III heart failure (HF) trial that Teva relinquished in June. It has ~12 months of cash runway plus a US\$90m equity finance facility, which will give a further 12 months' runway. It expects to report interim analyses of three Phase III programmes by end Q117, including the HF trial. We value Mesoblast ahead of these potential catalysts at A\$1.5bn (A\$3.84 per share).

INDUSTRY OUTLOOK

Mesoblast is the leading mesenchymal stem cell development company, with two platforms (MPCs, MSCs) and nine clinical candidates in Phase II and III. Alliances with JCR, Lonza and Teva underpin the key programmes.

Y/E Jun	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2015	32.4	(98.0)	(96.2)	(29.99)	N/A	N/A
2016	44.2	(86.3)	(87.4)	(0.20)	N/A	N/A
2017e	6.8	(80.3)	(81.0)	(21.24)	N/A	N/A
2018e	9.0	(80.3)	(82.6)	(21.65)	N/A	N/A

Sector: Pharma & healthcare

Price: 122.5p
Market cap: £43m
Market: LSE

Share price graph (p)

Company description

Midatech Pharma is an ambitious speciality pharmaceutical company, founded in 2000. The patented gold nanoparticle technology platform is developing therapeutics for several diseases such as diabetes and various cancers.

Price performance

%	1m	3m	12m
Actual	(8.4)	2.6	(52.8)
Relative*	(11.6)	(2.3)	(56.8)

* % Relative to local index

Analyst

Maxim Jacobs

Midatech Pharma (MTPH)

INVESTMENT SUMMARY

Midatech is a specialty pharma company with two key platforms focusing on commercializing and developing products in oncology, immunology & other therapeutic areas. The first is a drug conjugate delivery system based on gold nanoparticles. The second is a sustained release technology; proprietary microspheres that can be tailored to deliver a precise release profile for numerous drugs. An agreement is in place with Ophthotech to explore the use of the technology for sustained delivery formulations. It has also recently announced the dosing of a second patient for MTX110 in Diffuse Intrinsic Pontine Glioma, a very rare pediatric cancer. It currently markets a suite of oncology products in the US. Our forecasts are under review.


INDUSTRY OUTLOOK

The proprietary platforms develop products that address debilitating conditions with significant clinical needs. Applications that target larger market sizes are expected to be out-licensed for development and niche indications likely developed/marketed in-house.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2014	0.2	(9.9)	(10.1)	(100.6)	N/A	N/A
2015	1.4	(12.7)	(11.0)	(34.9)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €1.37
Market cap: €46m
Market: FRA

Share price graph (€)

Company description

Mologen is a German biotech company developing cancer immunotherapies. The lead product is lefitolimod (MGN1703) for metastatic colorectal cancer maintenance, SCLC and HIV. Development of MGN1601, a therapeutic renal cell vaccine, would be reinstituted on successful out-licensing of lefitolimod.

Price performance

%	1m	3m	12m
Actual	1.9	(22.3)	(64.3)
Relative*	(1.5)	(26.4)	(66.0)

* % Relative to local index

Analyst

Dr Susie Jana

Mologen (MGN)

INVESTMENT SUMMARY

Mologen is developing novel immunotherapies for use in the post-chemo maintenance setting in cancer and for the treatment of infectious diseases. Mologen's efforts are focused on its lead product candidate lefitolimod, which is in four clinical trials. IMPALA is a 540-pt pivotal study in metastatic colorectal cancer (mCRC) maintenance; full enrolment is expected by end-2016/Q117. Recruitment has completed for the 100-patient Phase II trial (IMPULSE) in small-cell lung cancer (SCLC) and analysis is expected to start at end-2016. The Phase I TEACH study to treat HIV (the first non-cancer study for MGN1703) has had its dosing regimen extended to six months; final results now expected H117. A 60-patient Phase I combination study of MGN1703 with Yervoy in solid tumours is now being conducted by MD Anderson. Cash of €15.3m as of 30th June 2016 alongside the recently announced capital increase should be sufficient to complete recruitment of IMPALA and reach top-line data from IMPULSE.

INDUSTRY OUTLOOK

Results for IMPALA are expected in 2018. Final overall survival (OS) data from IMPACT (Phase II in mCRC), and initial OS data from IMPULSE (expected H117) may offer fresh financing/partnering opportunities for lefitolimod before then.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(17.0)	(17.0)	(1.01)	N/A	N/A
2015	0.0	(20.4)	(20.5)	(0.99)	N/A	N/A
2016e	0.0	(24.9)	(24.9)	(1.10)	N/A	N/A
2017e	0.1	(25.7)	(25.8)	(1.14)	N/A	N/A

Sector: Pharma & healthcare

Price: €42.31
Market cap: €1123m
Market: FRA

Share price graph (€)

Company description

MorphoSys is a German biotechnology company that uses its proprietary antibody platforms to produce human antibodies for therapeutic use across a range of indications for partners and to develop its own pipeline.

Price performance

%	1m	3m	12m
Actual	16.5	8.6	(25.8)
Relative*	12.6	2.8	(29.5)

* % Relative to local index

Analyst

Maxim Jacobs

MorphoSys (MOR)

INVESTMENT SUMMARY

MorphoSys has a broad portfolio with 104 total programmes, 14 of those proprietary, including programmes for MOR208, MOR202 and MOR209. MOR208 is an Fc-enhanced antibody targeting CD19, which is being developed for DLBCL and CLL, while MOR202 is an anti-CD38 antibody in Phase I/IIa for multiple myeloma. MOR209, an anti-PSMA/CD3 antibody, is in Phase I trials for prostate cancer. Among the partnered programmes, J&J recently released blockbuster data for Guselkumab, an anti-IL-23 antibody, for psoriasis. Bimagrumb, partnered with Novartis, recently failed a Phase IIb/III trial in myositis, although other trials continue.


INDUSTRY OUTLOOK

The pharmaceutical industry is out-licensing more drug discovery and developing more biological products, both trends that should benefit MorphoSys. Also, there is increasing demand for novel therapies, such as those in MorphoSys's proprietary pipeline.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	64.0	(1.8)	(1.6)	(1.3)	N/A	N/A
2015	106.2	21.4	22.1	62.8	67.4	N/A
2016e	48.6	(59.5)	(58.6)	(153.4)	N/A	N/A
2017e	56.0	(67.4)	(66.5)	(172.1)	N/A	N/A

Sector: Pharma & healthcare

Price: €14.86
Market cap: €232m
Market: Euronext Paris

Share price graph (€)

Company description

Nanobiotix is a French nanomedicine company developing radiotherapy enhancers for the treatment of cancer. Lead product NBTXR3 is in pivotal clinical development in STS in Europe and is partnered with PharmaEngine in Asia-Pacific.

Price performance

%	1m	3m	12m
Actual	(7.2)	(12.7)	(8.2)
Relative*	(10.2)	(15.9)	(5.3)

* % Relative to local index

Analyst

Dr Jonas Peculis

Nanobiotix (NANO)

INVESTMENT SUMMARY

In September, Nanobiotix announced a submission for the CE mark approval of the lead product, radiotherapy enhancer NBTXR3, with the guided review time of nine months. Also, the company reported a slower than expected recruitment rate into Phase II/III sarcoma trial with the interim readout now likely in H117. In July, Nanobiotix announced positive data from its Phase I/II trial with head and neck (H&N) cancer patients, which is now the second indication with clinical data for NBTXR3 and the project can move into late stage studies. The first data from pre-clinical research in immuno-oncology area were released in May showing a promising proof-of-concept. Currently NBTXR3 is being investigated for a total of six indications including STS (Europe/Asia; Phase II/III; with PharmaEngine), liver cancers (Europe; HCC and metastases; Phase I/II), H&N cancers (Europe; Phase I/II) and rectal cancer (Phase I/II, run by PharmaEngine in Asia). We are updating our estimates.


INDUSTRY OUTLOOK

Radiotherapy is a cornerstone cancer treatment used in around 60% of all cancer patients. NanoXray aims to improve the benefits of current radiotherapy without increasing the risks to surrounding healthy tissue. The purely physical mechanism of action is supported by clinical data that have demonstrated encouraging efficacy with no serious adverse events.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	2.8	(9.3)	(9.5)	(74.14)	N/A	N/A
2015	4.0	(16.7)	(17.0)	(120.18)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharmaceutical & healthcare

Price: €0.74
Market cap: €32m
Market: Alternext Paris

Share price graph (€)

Company description

Neovacs is a French biotech company focused on the development of active immunotherapies for the treatment of lupus and dermatomyositis. A Phase II programme with IFN-alpha-Kinoid in lupus is underway.

Price performance

%	1m	3m	12m
Actual	(8.6)	(2.6)	5.9
Relative*	(11.6)	(6.2)	9.2

* % Relative to local index

Analyst

Dr John Savin

Neovacs (ALNEV)

INVESTMENT SUMMARY

Neovacs's lead project, IFN-Kinoid (IFN-K) for lupus, started a 178-patient EU, US and RoW Phase II in Q315. It expects data by mid-2017. This is based on clinical response and measurement of the interferon signature (IS), a diagnostic marker of lupus. CKD, a leading Korean pharmaceutical company, partnered the product for Korea in 2015; marketing may start in 2018. Neovacs plans to partner IFN-K, implying possible launches in 2021. VEGF Kinoid for cancer and AMD could start Phase I trials in 2017. Cash on 30 June 2016 was €9.2m after a French rights issue raised €8m gross at €0.85/share.

INDUSTRY OUTLOOK

Neovacs' nine-month efficacy Phase IIb data is due in H117; the Phase II includes a 12 patient US arm after FDA agreement. There is a programme in dermatomyositis (DM), an orphan skin and muscular condition that the rights issue will help to fund. Neovacs plans to evaluate INF Kinoid in Type 1 diabetes. A VEGF inhibitor is in preclinical for cancer and macular degeneration.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	0.2	(9.6)	(9.8)	(31.6)	N/A	N/A
2015	1.2	(11.2)	(11.2)	(26.8)	N/A	N/A
2016e	0.0	(14.0)	(14.0)	(26.5)	N/A	N/A
2017e	1.8	(12.6)	(12.6)	(20.5)	N/A	N/A

Sector: Pcare & household prd

Price: 68.5p
Market cap: £35m
Market: AIM

Share price graph (p)

Company description

NetScientific is a transatlantic biomedical and healthcare technology group. Its portfolio of five core investments and one material investment is focused on three main sectors: digital health (Wanda, Glucosense), diagnostics (Vortex, ProAxis, Glycotest) and therapeutics (PDS Biotech).

Price performance

%	1m	3m	12m
Actual	(9.3)	(6.8)	(47.9)
Relative*	(12.5)	(11.2)	(52.3)

* % Relative to local index

Analyst

Maxim Jacobs

NetScientific (NSCI)

INVESTMENT SUMMARY

NetScientific has a focused portfolio of potentially disruptive biomedical and healthcare technology investments. 2015 saw significant strategic changes, including senior management restructuring, bringing a new highly experienced CEO on board, rationalisation of the portfolio and new funding. The current focus is on digital health, diagnostics and therapeutics with the portfolio consisting of five core investments in which it has controlling stakes (Vortex, Wanda, ProAxis, Glycotest and Glucosense) and one material investment (PDS). The aim is to bring these to commercialisation over the next two years, with the ultimate goal of an exit, realising value for investors.

INDUSTRY OUTLOOK

NetScientific remains focused on sourcing, funding and building early- to mid-stage US and UK companies that are developing potentially breakthrough technologies in growing markets with unmet needs.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2014	0.0	(6.4)	(6.2)	(15.3)	N/A	N/A
2015	0.1	(11.5)	(11.3)	(24.4)	N/A	N/A
2016e	1.0	(20.0)	(19.9)	(29.2)	N/A	N/A
2017e	4.1	(18.1)	(18.8)	(27.8)	N/A	N/A

Sector: Pharma & healthcare

Price: CHF20.45
Market cap: CHF322m
Market: Swiss Stock Exchange

Share price graph (CHF)

Company description

Newron is a CNS-focused biotech. Sildenafil/Xadago (partnered with Zambon, US WorldMeds, Meiji Seika) for PD has been launched in Europe. The Sarizotan (Rett syndrome) pivotal trial STARS (Sarizotan Treatment of Apneas in Rett Syndrome) has initiated.

Price performance

%	1m	3m	12m
Actual	(9.1)	19.9	(27.5)
Relative*	(8.5)	21.2	(21.7)

* % Relative to local index

Analyst

Dr Susie Jana

Newron Pharmaceuticals (NWRN)

INVESTMENT SUMMARY

Newron's lead product, Xadago (sildenafil) for Parkinson's disease (PD) has been launched in 11 European countries and further launches are expected this year. It is now generating sales through commercial partner Zambon (ex-Japan/Asia). In the US, Xadago's NDA has been re-submitted and a decision is expected by end March 2017; FDA do not require additional clinical trials to be conducted. Other pipeline assets include sarizotan for Rett syndrome, the IND has been approved in the US and pivotal trial STARS (placebo-controlled Phase II/III trial) to investigate breathing disorders associated with RS has initiated. Data from the Phase II study of evenamide (NW-3509) for schizophrenia as an add-on to anti psychotics is expected in Q416. Newron recently raised CHF26.1m in a private placement that it expects will help fund operations through 2018.

INDUSTRY OUTLOOK

Parkinson's disease is a growing market. Xadago could have a unique position, with once-a-day dosing and a clean safety profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	1.6	(9.1)	(8.6)	(62.72)	N/A	N/A
2015	2.4	(17.6)	(18.3)	(117.21)	N/A	N/A
2016e	2.1	(23.6)	(23.3)	(147.51)	N/A	N/A
2017e	6.4	(11.7)	(11.3)	(71.77)	N/A	N/A

Sector: Pharma & healthcare

Price: €0.30
Market cap: €3m
Market: NASDAQ OMX First North

Share price graph (€)

Company description

Nexstim sells a non-invasive brain stimulation technology (nTMS) used as a diagnostic device for brain surgery planning (NBS System). The therapy system (NBT) failed in Phase III for stroke but an FDA submission is planned.

Price performance

%	1m	3m	12m
Actual	(38.8)	(63.0)	(94.8)
Relative*	(40.8)	(64.5)	(95.1)

* % Relative to local index

Analyst

Dr John Savin

Nexstim (NXTMH)

INVESTMENT SUMMARY

Nexstim has announced that the FDA requires further supporting data on stroke rehabilitation and that an small additional study using a different sham comparator will be required. The size and duration of this trial is unknown. Nexstim concludes that the FDA does not have any safety concerns about NBT safety. Nexstim estimates that the design of a limited size trial will be approved by the FDA in H1 2017. Phase III data showed that 66% of treated patients achieved the primary endpoint, but also that 'active' sham patients showed a similar response. Nexstim is financed until 2018 due to a SEDA and loan deal with Bracknor and Sitra; June 2016 cash was €1.8m. Cost savings of €2.3m/year have been implemented.


INDUSTRY OUTLOOK

Nexstim has developed a technology platform for diagnosis (NBS) and treatment (NBT) of vital motor and speech cortices in the brain. The system is CE marked and can be sold in the EU. Sales of NBS will be by distributors so management expect reduced revenues in 2016.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	2.2	(7.4)	(10.2)	(143.0)	N/A	N/A
2015	2.5	(10.0)	(9.6)	(119.0)	N/A	N/A
2016e	2.1	(7.7)	(8.3)	(91.0)	N/A	N/A
2017e	2.6	(5.2)	(5.4)	(40.0)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.53
Market cap: €119m
Market: Euronext Paris

Share price graph (€)

Company description

Onxeo is focused on orphan cancer and has three late-stage orphan oncology assets it could commercialise alone in Europe (Livatag, Beleodaq and Valdivie). Royalty-earning Beleodaq (belinostat) is launched in the US, along with two non-core, partnered, specialty products.

Price performance

%	1m	3m	12m
Actual	(17.9)	(21.2)	(31.4)
Relative*	(20.5)	(24.1)	(29.3)

* % Relative to local index

Analyst

Dr Jonas Peciulis

Onxeo (ONXEO)

INVESTMENT SUMMARY

In September, Onxeo announced exploratory preclinical data demonstrating that Livatag used in combination with immunotherapy drugs resulted in enhanced efficacy in hepatocellular carcinoma models. With its H116 results, Onxeo reported that R&D is progressing according to plan. Onxeo recently announced the development plans for recently acquired first-in-class AsiDNA, a signal-interfering DNA repair technology, which could move into clinic in 2017. A second lead product, Livatag, is in Phase III. ReLive and liver cancer data are expected in mid-2017. The 400-patient trial, which began in 2012, is >80% enrolled. Onxeo's third lead asset, Beleodaq, is already launched in the US with partner Spectrum for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL), generating royalty income for Onxeo. In September Onxeo raised €12.5m boosting its cash position to €34.9m at closing of the transaction.


INDUSTRY OUTLOOK

The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of the pharmaceutical industry to orphan drugs. Government incentives for drug development, as well as support from the regulatory bodies provide incentives for orphan drug developers.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	22.1	(4.5)	0.2	(5.03)	N/A	N/A
2015	3.5	(20.4)	(20.0)	(43.53)	N/A	N/A
2016e	3.5	(21.6)	(21.5)	(52.06)	N/A	N/A
2017e	8.7	(16.6)	(16.8)	(40.55)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$3.55
Market cap: US\$25m
Market: NASDAQ

Share price graph (US\$)

Company description

Opexa is developing personalized T-cell immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases such as neuromyelitis optica (NMO). Lead candidate Tcelna is in Phase IIb studies for secondary progressive MS (SPMS), with data expected in Q416.

Price performance

%	1m	3m	12m
Actual	2.0	(13.8)	5.0
Relative*	2.0	(12.7)	(0.2)

* % Relative to local index

Analyst

Pooya Hemami

Opexa Therapeutics (OPXA)

INVESTMENT SUMMARY

Opexa's Tcelna is advancing in Phase IIb studies in secondary progressive MS (SPMS), with data expected in early Q416. Tcelna is a patient-specific (autologous) immunotherapy that aims to suppress myelin-reactive T-cells (MRTCs) and thereby, curb autoimmune responses against myelin. Following the collection of a patient's own blood, the T-cells are screened against predefined self-reacting myelin protein targets. The dominant MRTC lines are isolated and expanded. An attenuated end-product is re-injected into the patient, aiming to generate a feedback response that will suppress the undesired circulating MRTCs.

INDUSTRY OUTLOOK

The firm is fully funded into Q117, and thus through the forecast attainment of Phase IIb data which, if positive, could sharply increase investor and stakeholder interest. Merck KGaA has an option to in-license Tcelna in MS. Opexa is also developing OPX-212 in neuromyelitis optica (NMO), a rare autoimmune disorder leading to vision loss and paralysis. Opexa believes it has mostly overcome the manufacturing challenges faced by this program, and envisions that if Merck in-licenses Tcelna, it will have resources to bring OPX-212 to Phase I trials.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	1.3	(14.7)	(15.1)	(432.9)	N/A	N/A
2015	2.6	(11.7)	(12.1)	(206.5)	N/A	N/A
2016e	27.0	15.7	15.4	218.9	1.6	1.7
2017e	0.0	(14.3)	(14.3)	(188.5)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$2.68
Market cap: US\$39m
Market: NASDAQ OTCQX

Share price graph (US\$)



Company description

Orexigen is a biopharmaceutical company focusing on obesity treatments. It will sell its sole product, Contrave, through its own salesforce in the US after taking back the rights from partner, Takeda. Contrave was launched in the US in Oct 2014 and approved in the EU in March 2015 under the trade name Mysimba.

Price performance

%	1m	3m	12m
Actual	(22.5)	(29.7)	(91.1)
Relative*	(22.6)	(28.8)	(91.6)

* % Relative to local index

Analyst

Maxim Jacobs

Orexigen Therapeutics (OREX)

INVESTMENT SUMMARY

Orexigen's obesity drug, Contrave, is an extended-release oral combination of long-marketed bupropion (Wellbutrin for depression) and Naltrexone (Revia for addiction). Now the leading branded obesity treatment in the US, Orexigen announced the acquisition of US rights to Contrave in the US from partner Takeda in mid-March. The company is now marketing the drug with a new dedicated salesforce of 160 reps. Contrave is approved under the brand Mysimba in the EU. The company recently announced a collaborative agreement with Valeant in 19 Central and Eastern European countries, including 11 in the EU where we can expect first launch by year end. A further agreement with Valeant in Canada has also been announced. Contrave, was also recently launched in South Korea through partner Kwang Dong.

INDUSTRY OUTLOOK


Orexigen is a biopharmaceutical company focusing on obesity treatments. Contrave was launched in the US in October 2014 and approved in the EU in March 2015, under the trade name Mysimba.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	55.5	(30.7)	(37.5)	(317.36)	N/A	1.2
2015	24.5	(60.3)	(67.3)	(523.81)	N/A	N/A
2016e	116.7	(89.7)	(63.3)	(431.49)	N/A	N/A
2017e	87.3	(95.2)	(110.7)	(716.09)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK43.50
Market cap: SEK1502m
Market: NASDAQ OMX Mid Cap

Share price graph (SEK)



Company description

Orexo is a Swedish speciality pharma company with expertise in drug delivery/reformulation technologies in particular sublingual formulations, and a US commercial infrastructure for opioid dependence therapy, Zubsolv.

Price performance

%	1m	3m	12m
Actual	(10.9)	(13.4)	(28.1)
Relative*	(13.2)	(18.6)	(32.5)

* % Relative to local index

Analyst

Lala Gregorek

Orexo (ORX)

INVESTMENT SUMMARY

Orexo has delivered on three key newsflow items, which should contribute to driving increased Zubsolv use in the treatment of opioid addiction. Submission of Zubsolv's MAA with the EMA means that first launch ex-US could come from 2018 onwards. FDA approval of a new low dose provides greater dosing flexibility. Positive data from the RESOLV real world study will be leveraged in educating new and existing prescribers to improve their treatment programmes. Ahead of Q316 results on October 20 we maintain our SEK5.13bn (SEK149/share) valuation highlighting that uncertainty due to the ongoing Actavis litigation continues to weigh on the share price; resolution is expected in H216.

INDUSTRY OUTLOOK

The US buprenorphine/naloxone market is worth >\$2bn. Opioid dependence diagnosis/treatment rates are low due to social stigma, limited access to therapy in parts of the US and affordability. Competition includes Suboxone film (Indivior), Bunavail (BDSI) and six generic bup/nal tablets.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2014	570.3	(12.5)	(52.6)	(165.0)	N/A	N/A
2015	643.2	(88.4)	(191.2)	(573.0)	N/A	N/A
2016e	752.9	60.7	24.8	54.0	80.6	5.0
2017e	989.4	156.2	137.3	221.0	19.7	7.7

Sector: Pharma & healthcare

Price: €2.83
Market cap: €81m
Market Madrid Stock Exchange

Share price graph (€)

Company description

Oryzon is a Spanish biotechnology company focused on developing novel epigenetic compounds. Lead compound ORY-1001 is partnered with Roche and is undergoing a Phase I/IIa study for acute leukaemia. ORY-2001 has potential for Alzheimer's disease and has been approved to enter Phase I.

Price performance

%	1m	3m	12m
Actual	0.0	(2.3)	N/A
Relative*	(2.6)	(6.0)	N/A

* % Relative to local index

Analyst

Dr Jonas Peculis

Oryzon Genomics (ORY)

INVESTMENT SUMMARY

Oryzon's core expertise lies in developing small molecule inhibitors for epigenetic targets. The lead product ORY-1001 is a first-in-class inhibitor of lysine specific demethylase 1 (LSD1) and currently is in Phase I/IIa for acute leukaemia, with the results potentially out by end 2016. Preclinical models showed that LSD1 is a key effector causing arrest in cell differentiation in subtypes of acute myeloid leukaemia (AML) and that the inhibition of this target could potentially lead to an effective treatment. ORY-1001 is partnered with Roche, which can take over further development after the end of the ongoing Phase I/IIa. Oryzon's second product, ORY-2001, targets Alzheimer's disease (AD) and has entered a Phase I trial in early 2016. ORY-3001 has been recently revealed as the third product to enter pre-clinical development in non-oncological indications.


INDUSTRY OUTLOOK

Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	15.5	11.7	11.3	48.3	5.9	5.4
2015	7.2	0.7	(0.1)	(0.6)	N/A	64.4
2016e	3.9	(3.7)	(4.7)	(15.1)	N/A	N/A
2017e	2.5	(4.6)	(5.6)	(19.5)	N/A	N/A

Sector: Pharma & healthcare

Price: 3.1p
Market cap: £95m
Market LSE

Share price graph (p)

Company description

Oxford BioMedica is a leader in gene and cell therapy. The lentivector technology is wide ranging, covering in vivo and ex vivo vector products. The technology underpins the proprietary clinical development pipeline in addition to third party manufacturing contracts which add validation to the platform.

Price performance

%	1m	3m	12m
Actual	(9.7)	(29.1)	(59.6)
Relative*	(12.9)	(32.5)	(63.0)

* % Relative to local index

Analyst

Dr Susie Jana

Oxford BioMedica (OXB)

INVESTMENT SUMMARY

Oxford BioMedica's near-term outlook has been transformed by its specialist production capabilities. Interim results announced a plan to spin out or out-license Phase I/II studies for OXB-102 (Parkinson's disease), OXB-202 (corneal graft rejection) and OXB-302 (CAR-T 5T4) for solid cancers. The expansion of the manufacturing capacity for third parties (e.g Novartis's CTL019/CART-019) is now complete (Recent MHRA GMP manufacturing approvals); with Novartis indicating a 2017 filing for CTL019, Oxford should start earning royalties and substantial manufacturing fees (up to \$76m over three years). This growing manufacturing revenue stream provides technology know-how validation and, more importantly, cash to fund R&D of the proprietary pipeline. The recent net £10m equity raise should enable OXB to become cash flow positive in the mid-term. In the longer term, additional collaborations for the late-stage projects, licence income from the patent estate and pipeline progress can be expected. Our forecasts are currently under review.

INDUSTRY OUTLOOK

Cell- and gene-therapy is the focus of much industry attention as it can dramatically alter the outcomes of many diseases. The proprietary lentivector platform is a flexible and efficient system that is promising in many indications.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2014	13.6	(9.5)	(10.4)	(0.41)	N/A	N/A
2015	15.9	(12.5)	(16.6)	(0.49)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: NZ\$0.45
Market cap: NZ\$172m
Market: NZSX

Share price graph (NZ\$)

Company description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

Price performance

%	1m	3m	12m
Actual	(6.3)	(13.5)	(2.2)
Relative*	(1.7)	(10.5)	(15.0)

* % Relative to local index

Analyst

Maxim Jacobs

Pacific Edge (PEB)

INVESTMENT SUMMARY

Pacific Edge's lead product, Cxbladder Detect, is a molecular diagnostic for the early detection and management of bladder cancer in patients with haematuria. Launched in the US, New Zealand and Australia, we expect news related to the success of numerous User Programmes over the next 12 months. Kaiser Permanente Southern California is recruiting c 2,000 patients in a large User Programme, evaluating follow-on diagnostic test Cxbladder Triage. In late February, the company announced the signing of a Federal Supply Schedule to the Veterans Administration, allowing the marketing of Cxbladder tests within the organization - the largest integrated healthcare system in the US.


INDUSTRY OUTLOOK

Molecular diagnostics is a growing, but increasingly competitive field. Lead time from the initiation of user programmes to payment can be long.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	3.6	(10.5)	(11.1)	(3.5)	N/A	N/A
2016	6.4	(14.9)	(15.5)	(4.1)	N/A	N/A
2017e	11.4	(6.7)	(7.4)	(1.9)	N/A	N/A
2018e	24.4	4.7	4.0	0.6	75.0	30.0

Sector: Pharma & healthcare

Price: €2.87
Market cap: €160m
Market: FRA

Share price graph (€)

Company description

PAION is an emerging specialty pharma company developing anaesthesia products. Its lead product, remimazolam, is partnered with Yichang in China, Hana Pharma in S Korea, Cosmo in the US, Pendopharm in Canada and R-Pharm in CIS, Turkey and MENA.

Price performance

%	1m	3m	12m
Actual	28.1	35.8	28.8
Relative*	23.8	28.6	22.4

* % Relative to local index

Analyst

Dr Dennis Hulme

Paion (PA8)

INVESTMENT SUMMARY

Paion reported positive top-line results from the first of two US pivotal studies of short-acting anaesthetic remimazolam in procedural sedation, and has out-licensed US rights to Cosmo Pharmaceuticals for c €20m of cash, €42.5m potential milestones and a 20-25% royalty. In the pivotal trial 91% of patients in the remimazolam arm achieved the primary outcome vs 5% on placebo, while the safety profile was consistent with previous studies. Recruitment in the second Phase III, in bronchoscopy patients, is expected to complete in Q217. Planned changes in the US reimbursement of day procedures favouring less supervision by anaesthetists could incentivise gastroenterologists to use remimazolam. Japan's PMDA advised that the data packages for remimazolam for general anaesthesia were ready for filing (we expect filing in H217). The €32.1m cash at 30 June plus €10m upfront payment from Cosmo received in July is sufficient to complete ongoing Phase III development and preparation of filing for procedural sedation in the US (we anticipate filing in 2018).


INDUSTRY OUTLOOK

Remimazolam has important advantages over competing products, including fast onset and offset of action with lower risk of cardiopulmonary events than the standard of care midazolam and propofol, and a reversal agent exists if there is over sedation.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	3.5	(11.5)	(11.6)	(22.9)	N/A	N/A
2015	0.1	(34.1)	(34.0)	(55.7)	N/A	N/A
2016e	10.1	(20.6)	(20.6)	(30.7)	N/A	N/A
2017e	2.2	(8.4)	(8.4)	(13.3)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$3.19
Market cap: US\$528m
Market: NASDAQ

Share price graph (US\$)

Company description

PDL has reinvented itself through a three-pronged strategy: investing in royalty streams of marketed and development-stage therapeutics and providing high-yield debt financing to device & diagnostic companies with near-term product launches.

Price performance

%	1m	3m	12m
Actual	0.6	(6.7)	(30.3)
Relative*	0.6	(5.5)	(33.8)

* % Relative to local index

Analyst

Maxim Jacobs

PDL BioPharma (PDLI)

INVESTMENT SUMMARY

PDL BioPharma is reinventing itself as a healthcare-focused finance company through a three-pronged strategy: investing in royalty streams, providing high-yield financing to life science companies with near-term product launches as well as through the purchase of approved drugs to be sold by Noden Pharma (of which they own >88%) on a high margin basis. This strategy allows investors to gain exposure in healthcare through a relatively low-risk, diversified vehicle. Weakness in debt and equity markets has led to more opportunities to invest for the company than ever.


INDUSTRY OUTLOOK

PDL BioPharma is one of the only companies that will give broad exposure to diverse royalty streams as well as corporate debt and high margin approved products.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	581.2	546.3	501.3	203.66	1.6	1.7
2015	590.4	550.4	530.1	203.69	1.6	1.7
2016e	224.9	154.8	134.5	53.27	6.0	7.5
2017e	197.9	98.5	72.5	31.61	10.1	47.3

Sector: Pharma & healthcare

Price: €2.75
Market cap: €611m
Market: Madrid Stock Exchange

Share price graph (€)

Company description

PharmaMar is a Spanish biopharmaceutical group with a core focus on the development of marine-based drugs for cancer. Yondelis is approved in the EU and US, and partnered with Janssen (J&J) in the US and Taiho in Japan.

Price performance

%	1m	3m	12m
Actual	1.3	21.7	(31.3)
Relative*	(1.4)	17.0	(20.7)

* % Relative to local index

Analyst

Dr Dennis Hulme

PharmaMar (PHM)

INVESTMENT SUMMARY

PharmaMar restructured in late 2015 to concentrate on its potentially high-growth marine oncology activities. PharmaMar has built a pipeline of first-in-class cancer drugs for development with strategic partners. Royalty income flowing from the approvals for Yondelis for soft tissue sarcoma in Japan and the US in September and October 2015, respectively, should drive strong profit growth from 2017. The 420-patient CORAIL Phase III trial of PM1183 in platinum-resistant ovarian cancer was cleared to continue in August after an interim futility analysis on the first 210 patients. Another pivotal study of PM1183 was initiated in August; the 600-patient Phase III ATLANTIS study will evaluate PM1183 in combination with doxorubicin in patients with small cell lung cancer. A Phase II trial of the drug in BRCA 1/2 breast cancer achieved a 41% ORR. PharmaMar has filed for approval of Aplidin in Europe for multiple myeloma following positive Phase III results reported in March, while a pivotal study of Aplidin in angioimmunoblastic T-cell lymphoma was initiated in June.


INDUSTRY OUTLOOK

PharmaMar's oncology portfolio has been validated through multiple global partnerships, eg J&J in the US and Taiho in Japan (over Yondelis) and Chugai in certain EU countries (for Aplidin).

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	149.7	25.7	16.3	6.8	40.4	26.0
2015	162.0	19.3	6.5	3.2	85.9	59.9
2016e	169.6	(7.8)	(19.6)	(9.5)	N/A	N/A
2017e	181.7	15.1	3.6	0.9	305.6	48.4

Sector: Pharma & healthcare

Price: NOK39.00
Market cap: NOK840m
Market: Oslo

Share price graph (NOK)

Company description

Photocure specialises in photodynamic therapy. Its bladder cancer imaging product is sold as Hexvix in Europe and Cysview in the US. Photocure handles the marketing in Nordic countries and the US, while Ipsen is its marketing partner in the EU.

Price performance

%	1m	3m	12m
Actual	(4.4)	(4.4)	(2.5)
Relative*	(10.0)	(5.5)	(0.8)

* % Relative to local index

Analyst

Maxim Jacobs

Photocure (PHO)

INVESTMENT SUMMARY

Photocure specialises in photodynamic therapy. Its bladder cancer imaging product is sold as Hexvix in Europe and Cysview in the US. It improves detection rates and helps prolong recurrence-free survival. Photocure handles the marketing in Nordic countries and the US, while Ipsen is its marketing partner in the EU. Cevira is a Phase III-ready product for HPV-related diseases of the cervix and Visonac is a Phase III-ready product for acne. Both Cevira and Visonac are the subject of partnership discussions.


INDUSTRY OUTLOOK

Photocure is a photodynamic therapy company focused on bladder cancer imaging, HPV-related diseases and acne. As its products typically are a combination of a drug and a device, hurdles for generics are typically higher than with other therapeutics.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2014	129.0	(4.2)	1.5	7.0	557.1	N/A
2015	134.7	(18.1)	(17.4)	(82.0)	N/A	N/A
2016e	132.6	(16.5)	(21.3)	(99.0)	N/A	N/A
2017e	150.4	(8.7)	(13.4)	(61.0)	N/A	220.0

Sector: Pharma & healthcare

Price: €5.73
Market cap: €73m
Market: Euronext Paris

Share price graph (€)

Company description

Pixium is a French medical device company developing retinal implants for patients with complete vision loss. Its lead product Iris is an epi-retinal implant scheduled for CE mark approval in mid-2016; a sub-retinal implant (Prima) is in pre-clinical.

Price performance

%	1m	3m	12m
Actual	(15.9)	(25.3)	(0.5)
Relative*	(18.6)	(28.0)	2.6

* % Relative to local index

Analyst

Pooya Hemami

Pixium Vision (PIX)

INVESTMENT SUMMARY

Pixium Vision is developing two different retinal implant systems that transform images into electrical signals to restore vision in patients with severe retinal disease. The devices consist of an implant and a pair of glasses with an embedded camera, and handheld control. Pixium received CE Mark approval for the Iris II epiretinal implant in July 2016. It is also conducting EU clinical trials with Iris II and interim data should assist reimbursement applications in EU markets. Positive pre-clinical data with Prima, a subretinal implant potentially providing better visual acuity than Iris II, should support first human testing in H216. Pixium held €16m in cash at 30 June 2016 and secured up to €11m in debt financing in September 2016.


INDUSTRY OUTLOOK

Second Sight (EYES) is commercialising an epiretinal implant (Argus II) in the US and EU. The Iris II offers 150 electrodes (vs 60 on Argus II), potentially offering better vision, while also being the first potentially explantable (and upgradable) epiretinal implant. Prima is less surgically invasive and could potentially be a viable treatment option for macular degeneration patients.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	2.4	(10.8)	(11.6)	(118.43)	N/A	N/A
2015	3.3	(14.6)	(15.6)	(122.88)	N/A	N/A
2016e	2.9	(13.3)	(14.2)	(111.06)	N/A	N/A
2017e	5.5	(22.9)	(24.1)	(188.56)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.13
Market cap: A\$27m
Market: ASX

Share price graph (A\$)

Company description

Prescient Therapeutics (previously Virax) is an ASX-listed biotechnology company focused on developing novel products for the treatment of cancer. It has two products, PTX-100 and PTX-200 in clinical development for a range of cancers.

Price performance

%	1m	3m	12m
Actual	32.7	23.8	126.0
Relative*	30.4	24.9	118.2

* % Relative to local index

Analyst

Dr Dennis Hulme

Prescient Therapeutics (PTX)

INVESTMENT SUMMARY

Prescient is developing two promising anti-cancer compounds that target major tumour survival pathways. The company's most advanced compound, PTX-200, is in Phase Ib/II trials in breast and ovarian cancers, while a Phase Ib trial in acute myeloid leukaemia is also planned. The breast cancer study has identified the recommended Phase II dose, and researchers have initiated an expansion cohort in 12 patients to better characterise the safety profile. The second drug, PTX-100, is expected to begin a Phase Ib trial in breast cancer in 2017. Pro forma cash is c A\$11m. We are currently updating our model for FY16 results.


INDUSTRY OUTLOOK

PTX-200 is a specific inhibitor of Akt, a key component of one of the Ras signalling pathways. The three Ras genes in humans (HRAS, KRAS and NRAS) are the most common oncogenes in human cancer; mutations that permanently activate Ras are found in 20-25% of all human tumours. Celator Pharmaceuticals saw its stock price increase 10-fold after reporting positive results in a Phase III AML trial in March 2016, highlighting the strong interest in potential new AML drugs. Celator was subsequently acquired by Jazz Pharmaceuticals for c US\$1.5bn.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(1.8)	(1.8)	(5.94)	N/A	N/A
2015	0.3	(2.1)	(2.1)	(4.28)	N/A	N/A
2016e	0.2	(2.0)	(1.9)	(2.57)	N/A	N/A
2017e	0.3	(10.1)	(10.0)	(10.70)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.04
Market cap: A\$77m
Market: ASX

Share price graph (A\$)

Company description

Prima's pipeline is based on three products using a LAG-3 immune control system: IMP321 for cancer chemo-immunotherapy and partnered products IMP731 (GSK) and IMP701 (Novartis). Ph II asset CVac is an autologous dendritic cell vaccine.

Price performance

%	1m	3m	12m
Actual	(2.6)	(11.9)	(36.2)
Relative*	(4.3)	(11.2)	(38.4)

* % Relative to local index

Analyst

Dr Dennis Hulme

Prima BioMed (PRR)

INVESTMENT SUMMARY

Prima BioMed has a pipeline of four clinical assets (one partnered with GSK and a second partnered with Novartis), the three most promising ones based on a promising and versatile immunotherapy target Lymphocyte activation gene-3, LAG-3. The lead in-house LAG-3 product, IMP321, is being developed initially in metastatic breast cancer in combination with chemotherapy (211-patient randomised Phase IIb initiated Q415) and in melanoma in combination with the anti-PD1 checkpoint inhibitor, Keytruda (Phase I initiated January 2016). Novartis and GSK have commenced clinical trials of partnered LAG-3 programmes, providing additional validation for the LAG-3 technology. Prima out-licensed its CVac dendritic vaccine, which improved overall survival in second remission ovarian cancer patients in the CAN-003 Phase II trial, to US-based Sydys in April 2016. We are currently updating our model for FY16 results.

INDUSTRY OUTLOOK

Immunotherapies are among the most promising class of products for cancer and autoimmune diseases. The LAG-3 products are potentially first-in-class, each with distinct mechanisms and applications.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	2.0	(14.0)	(13.3)	(1.1)	N/A	N/A
2015	1.3	(13.3)	(12.9)	(0.9)	N/A	N/A
2016e	2.2	(13.8)	(15.1)	(0.9)	N/A	N/A
2017e	1.1	(15.1)	(14.7)	(0.7)	N/A	N/A

Sector: Pharma & healthcare

Price: €18.98
Market cap: €141m
Market: Euronext Amsterdam

Share price graph (€)



Company description

Probiobdrug is a biopharma company developing its clinical pipeline for the treatment of Alzheimer's. Lead product candidate, PQ912, has entered Ph IIa. PQ912 is a small molecule inhibitor of QC, which is essential for the formation of pGlu-Abeta. Two further products are in preclinical stages.

Price performance

%	1m	3m	12m
Actual	(5.0)	4.3	(4.0)
Relative*	(7.9)	3.2	(5.1)

* % Relative to local index

Analyst

Dr Jonas Peciuslis

Probiobdrug (PBD)

INVESTMENT SUMMARY

Probiobdrug is developing a clinical pipeline focusing on the novel target of pGlu-Abeta, a toxic variant of amyloid-beta (Abeta) that has been implicated in the initiation and sustainment of the pathological cascade that leads to Alzheimer's disease (AD). Lead candidate PQ912 is an inhibitor of the enzyme glutaminyl cyclase, which is essential for the formation of pGlu-Abeta. Recruitment is on track for the Phase IIa study, SAPHIR, in early AD, with safety data expected by end of 2016 and exploratory efficacy data 3-4 months later. Recently, Probiobdrug announced positive results from the first combination study of PQ912 with the second product specific monoclonal antibody PBD-C06, which showed an additive effect in lowering toxic Abeta. The capital raise of €14.9m in September extends the cash runway well beyond the SAPHIR data readout, when Probiobdrug may seek to partner PQ912.

INDUSTRY OUTLOOK

There are 44m dementia sufferers worldwide, 60% of whom have AD. The lack of disease-modifying therapies leaves a vast unmet clinical need. This, combined with increasing understanding of the disease process and the development of biomarkers, has led to increased optimism that a disease-modifying therapy may be found.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(11.2)	(11.4)	(234.7)	N/A	N/A
2015	0.0	(13.3)	(13.5)	(196.1)	N/A	N/A
2016e	0.0	(14.3)	(14.2)	(190.7)	N/A	N/A
2017e	0.0	(11.0)	(11.0)	(148.2)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.14
Market cap: A\$29m
Market: ASX

Share price graph (A\$)



Company description

Regeneus is a clinical-stage regenerative medicine company developing innovative cell-based therapies for the human & animal health markets.

Price performance

%	1m	3m	12m
Actual	3.7	3.7	16.7
Relative*	1.9	4.6	12.7

* % Relative to local index

Analyst

Dr Dennis Hulme

Regeneus (RGS)

INVESTMENT SUMMARY

Regeneus is developing and commercialising its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans. In May 2016, the company announced the completion of enrolment of all 20 patients in the STEP randomised Phase I/II study of Progenza (allogeneic) in human osteoarthritis, and confirmed no safety concerns had been identified. Recent Japanese legislation offers an accelerated path to market for regenerative medicine products and the company is currently working to finalise manufacturing and clinical development partnerships in Japan. Regeneus also holds global rights to autologous cancer vaccine technologies for human (RGSH4K - Phase I began in Q215) and veterinary (Kvax) applications. Cash at 30 June was A\$0.5m.


INDUSTRY OUTLOOK

Regeneus has firmed up its strategy to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development. It has partnered with a top-5 global animal health company for development of CryoShot Canine, and will seek to identify wider applications of its off-the-shelf Progenza human stem cells, beyond the initial development for osteoarthritis. Cancer immunotherapy, including cancer vaccines such as RGSH4K, is a biotech hotspot.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	1.9	(9.8)	(6.6)	(3.15)	N/A	N/A
2016	1.7	(6.1)	(3.6)	(1.70)	N/A	N/A
2017e	2.0	(6.1)	(3.6)	(1.73)	N/A	N/A
2018e	2.6	(5.6)	(3.2)	(1.53)	N/A	N/A

Sector: Pharma & healthcare

Price: 2.4p
Market cap: £75m
Market: LSE

Share price graph (p)

Company description

ReNeuron is a UK biotech company developing allogeneic cell therapies: CTX neural stem cell products for stroke disability (Phase IIa) and critical limb ischaemia (Phase I); and human retinal progenitor cells for retinitis pigmentosa (Phase I/II).

Price performance

%	1m	3m	12m
Actual	(9.5)	(20.8)	(42.1)
Relative*	(12.7)	(24.6)	(46.9)

* % Relative to local index

Analyst

Dr Linda Pomeroy

ReNeuron Group (RENE)

INVESTMENT SUMMARY

ReNeuron is funded (£65.7m in cash at 31 March 2016) to undertake pivotal studies with two cell therapy-based programmes. This includes the CTX neural stem cell programme (a 21-patient Phase II study ongoing in stroke disability and six-patient Phase I for critical limb ischaemia) and the hRPC (human retinal progenitor cells) programme for retinitis pigmentosa (a 15-patient Phase I/II trial is underway in the US). Pivotal Phase II/III studies are planned for the stroke and RP programmes. ReNeuron recently announced promising early pre-clinical data for its exosome nanomedicine platform in oncology, with the first clinical target being glioblastoma multiforme. The company recently relocated to a new GMP cell manufacturing and research facility in South Wales (funded by a £7.8m Welsh government grant).


INDUSTRY OUTLOOK

Stroke is a high-risk indication, but ReNeuron is attempting to demonstrate a meaningful reduction in disability that would offer a compelling case for further development and/or partnering (Phase IIa data in Q416 will determine next steps). The hRPC programme has Orphan (EU/US) and Fast Track (US) designation with a potentially pivotal Phase II/III study planned for 2017.

Y/E Mar	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	0.0	(10.3)	(10.3)	(0.50)	N/A	N/A
2016	0.0	(13.6)	(12.8)	(0.44)	N/A	N/A
2017e	0.0	(27.1)	(26.7)	(0.74)	N/A	N/A
2018e	0.0	(32.8)	(32.6)	(0.91)	N/A	N/A

Sector: Pharma & healthcare

Price: 25.55PLN
Market cap: PLN343m
Market: Warsaw Stock Exchange

Share price graph (PLN)

Company description

Selvita is a drug discovery services provider based in Poland. It employs 352 staff (30% PhDs) and operates two main business units: Innovations Platform (internal NME pipeline) and Research Services (medicinal chemistry/biology, biochemistry).

Price performance

%	1m	3m	12m
Actual	9.7	16.7	21.6
Relative*	10.5	21.2	49.9

* % Relative to local index

Analyst

Dr Jonas Peculis

Selvita (SLV)

INVESTMENT SUMMARY

Selvita is a rapidly emerging drug discovery and research services company. Operating off a solid base from its profitable contract research business, the company is also developing its own novel oncology compounds, currently self-financed but potentially through partnerships. Most advanced are two preclinical kinase inhibitor programmes: SEL24 (dual PIM/FLT3 inhibitor, for AML) expected to enter Phase I in Q416, and SEL120 (CDK8 inhibitor, colon cancer and other malignancies) about to begin IND-enabling studies and potentially move to Phase I in 2017. Multiple collaborations signed with partners such as Merck KGaA, H3 Biomedicine (Eisai) and most recently joint venture with Epidarex Capital to form Nodthera validate Selvita's research capabilities. Cash of PLN31m at end of August 2016, bolstered by profits from research service contracts, is sufficient to fund current activities.

INDUSTRY OUTLOOK

The profiles of SEL24 and SEL120 are potentially unique when compared to existing clinical-stage competitors and both candidates may offer efficacy and safety advantages. Contract research is a fiercely competitive, but still rapidly growing market and we believe Selvita's geographical location and lower cost benefits make it well placed to compete.

Y/E Dec	Revenue (PLNm)	EBITDA (PLNm)	PBT (PLNm)	EPS (gr)	P/E (x)	P/CF (x)
2014	41.6	7.6	5.4	55.91	45.7	N/A
2015	56.1	10.2	7.6	83.58	30.6	N/A
2016e	66.3	5.9	3.6	23.58	108.4	N/A
2017e	76.6	9.9	5.8	42.32	60.4	N/A

Sector: Pharma & healthcare

Price: 119.2p
Market cap: £83m
Market: AIM

Share price graph (p)

Company description

Silence Therapeutics is a leading UK RNA therapeutics development company, with proprietary RNA interference (RNAi) technology and delivery systems. It is expanding into targeted gene editing technology (using the CRISPR/Cas9 system) and non-liposomal conjugation delivery systems.

Price performance

%	1m	3m	12m
Actual	1.9	7.9	(43.2)
Relative*	(1.7)	2.8	(48.0)

* % Relative to local index

Analyst

Dr Linda Pomeroy

Silence Therapeutics (SLN)

INVESTMENT SUMMARY

Silence Therapeutics is a leading RNA therapeutics development company, with proprietary RNA interference (RNAi) technology and delivery systems. It has a broad genetic toolkit enabling the key areas of RNA therapeutics, siRNA (silencing genes) and mRNA (upregulating genes). It is able to use its platform to target a wide range of tissues and therefore potential indications. It is also applying its platform technology to gene editing, an area of high focus and potential. Silence already has a licence deal with Quark for its AtuRNAi technology, which has recently progressed into a Phase III clinical trial in delayed graft function (DGF) and Phase II for acute kidney injury (AKI). Silence held €47.6m in cash at H116, following a c £40m equity issue in 2015.

INDUSTRY OUTLOOK

RNA therapeutics is an increasingly high profile sector of the biotechnology industry. Improvements in technology and a growing body of clinical evidence has created a resurgence of interest in the sector. Developments in RNA therapeutics now offer a number of options, which are being used to target a number of disease areas. RNA therapies are potentially going to be in the market in the next couple of years.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2014	0.0	(11.8)	(11.7)	(21.51)	N/A	N/A
2015	0.0	(9.6)	(9.4)	(10.38)	N/A	N/A
2016e	0.0	(11.2)	(11.1)	(13.95)	N/A	N/A
2017e	0.0	(14.0)	(14.1)	(17.77)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$0.90
Market cap: US\$11m
Market: NASDAQ

Share price graph (US\$)

Company description

StemCells is focused on developing and commercialising stem cell-based therapeutics. Its lead product, HuCNS-SC (human neural stem cells), is in clinical development for spinal cord injury and age-related macular degeneration.

Price performance

%	1m	3m	12m
Actual	(35.0)	137.6	(81.2)
Relative*	(35.0)	140.6	(82.1)

* % Relative to local index

Analyst

Maxim Jacobs

StemCells (STEM)

INVESTMENT SUMMARY

StemCells Inc. is a development stage cell therapy company. After initially reporting highly encouraging data from the first cohort of its Phase II PATHWAY study in spinal cord injury (SCI), the company announced that an interim analysis of the second cohort suggested that the trial was unlikely to succeed. Hence, they announced an orderly wind-down of operations. Subsequent to that, they announced a strategic merger with Microbot Medical, a robotics based medical device company.

INDUSTRY OUTLOOK


StemCells is a US company developing stem cell-based therapeutics. Stemcells' HuCNS-SC are allogeneic cells derived from donor human neural stem cells, adopting a homologous approach.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	1.0	(32.2)	(32.2)	(6.8)	N/A	N/A
2015	0.1	(37.5)	(36.8)	(4.6)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €55.16
Market cap: €654m
Market: Deutsche Börse

Share price graph (€)



Company description

Stratec designs and manufactures OEM diagnostic instruments. Design and assembly of systems from modules is in Germany and Switzerland. It now has five subsidiary businesses.

Price performance

%	1m	3m	12m
Actual	0.8	6.1	14.1
Relative*	(2.5)	0.4	8.5

* % Relative to local index

Analyst

Dr John Savin

Stratec Biomedical (SBS)

INVESTMENT SUMMARY

Stratec has completed the acquisition of an Austrian business, Sony DADC Biosciences, that designs and manufactures complex precision consumables for high-end biomedical and diagnostic systems. This is an excellent strategic fit as it allows Stratec to integrate high-value consumables into system designs and accumulate recurring revenues: Stratec expects 2016 sales to increase to between €175m and €182m following the time apportioned consolidation of Diatron and STRATEC Consumables. An EBIT margin of between 16.0% and 17.5% is expected in 2016. Sales in 2017 are expected to be between €205 and €220m, with a slight increase in EBIT margin over 2016.

INDUSTRY OUTLOOK


The Diatron acquisition adds about €25m revenue in FY16 and €37m in FY17. Sony DADC will add over €5m in 2016 and perhaps €20m in 2017 making Edison forecast revenues of €183.5m in 2016 and rising to perhaps €220m in 2017. Stratec has a €50m bridging loan to part fund the €97m of acquisitions to date in 2016.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	144.9	31.1	29.7	215.6	25.6	16.8
2015	146.9	36.1	34.9	252.9	21.8	20.2
2016e	183.5	38.0	35.6	248.9	22.2	21.8
2017e	220.1	43.6	41.2	286.1	19.3	15.5

Sector: Pharma & healthcare

Price: US\$4.07
Market cap: US\$59m
Market: NASDAQ

Share price graph (US\$)



Company description

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The lead asset is Qinprezo, a chemotherapy for AML in the approval process in the EU. The company has also developed SNS-062, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I.

Price performance

%	1m	3m	12m
Actual	(8.7)	30.4	(31.8)
Relative*	(8.8)	32.1	(35.1)

* % Relative to local index

Analyst

Maxim Jacobs

Sunesis Pharmaceuticals (SNSS)

INVESTMENT SUMMARY

Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead program is Qinprezo, a quinolone derivative for relapsed/refractory acute myeloid leukemia (AML) without the dose limiting cardiotoxicity of anthracyclines. The FDA discouraged submitting an NDA after it missed its primary endpoint, but significant potential remains in Europe where Qinprezo has data comparable to those used in other related approvals. Sunesis is also advancing its clinical asset, SNS-062, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice a day dosing. A Phase I/IIa is expected to begin around year-end.

INDUSTRY OUTLOOK

Sunesis is an oncology company with a late-stage asset, potentially near European approval, as well as preclinical assets utilising promising targets, making it an attractive partner.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	5.7	(41.3)	(43.0)	(430.0)	N/A	N/A
2015	3.1	(35.8)	(36.7)	(302.0)	N/A	N/A
2016e	2.4	(35.7)	(37.0)	(253.0)	N/A	N/A
2017e	1.7	(45.6)	(49.1)	(320.0)	N/A	N/A

Sector: Pharma & healthcare

Price: €1.28
Market cap: €48m
Market: FRA

Share price graph (€)

Company description

Sygnis develops tools for molecular biologists. Its main focus is in the field of polymerases for the amplification and sequencing of DNA. Sygnis launched its own TruePrime and SunScript branded products in 2015.

Price performance

%	1m	3m	12m
Actual	(1.8)	(7.3)	(42.6)
Relative*	(5.1)	(12.3)	(45.5)

* % Relative to local index

Analyst

Dr John Savin

Sygnis (LIO1)

INVESTMENT SUMMARY

Following the acquisition of Expedeon, Sygnis expects to achieve profitability in 2017 if sales grow to about €7m; management is focused on achieving sales synergies and controlling costs. The acquisition was funded by issuing 20.54m shares at €1.10 each including a cash fund-raising of €5.3m gross. Sygnis produces innovative molecular biology kits, while Expedeon makes well-designed products for protein analysis. Expedeon has a UK- and US-focused, 13-person sales and marketing team and a five-year sales CAGR of about 20%. Integration and sales training will take most of 2016. Guidance on sales is expected in November 2016. Cash as of 30th June 2016 was €2.4m.


INDUSTRY OUTLOOK

Sygnis has completed a rights offering and placement issuing 20.5m shares. Of these, €5.3 million gross was received in cash and the rest (15.7m shares) used in kind to buy Expedeon shares. Sygnis is working on a new research kit for liquid biopsy testing to detect fragments of cancer DNA in blood.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.4	(1.7)	(1.9)	(19.27)	N/A	N/A
2015	0.6	(2.4)	(2.6)	(19.31)	N/A	N/A
2016e	3.2	(0.9)	(1.0)	(3.79)	N/A	N/A
2017e	6.9	0.8	0.7	1.94	66.0	9548.8

Sector: Pharma & healthcare

Price: ¥245.00
Market cap: ¥11139m
Market: Tokyo

Share price graph (¥)

Company description

SymBio is a specialty pharma company with a focus on oncology, haematology and pain management. Treakisym was in-licensed from Astellas in 2005. Rigosertib was in-licensed from Onconova and IONSYS in-licensed from The Medicines Company.

Price performance

%	1m	3m	12m
Actual	0.4	4.7	9.9
Relative*	(2.9)	1.7	22.0

* % Relative to local index

Analyst

Maxim Jacobs

SymBio Pharmaceuticals (4582)

INVESTMENT SUMMARY

SymBio is well on the way to becoming a key speciality pharma partner for Asia-Pacific markets. The company has in-licensing deals for two orphan blood cancer products and has signed a deal for a pain management device. Treakisym is approved for r/r iNHL/MCL, and recently, CLL patients and is awaiting approval for additional indications. Rigosertib is in development for myelodysplastic syndromes and has started a pivotal Phase III global study, with FPI enrolled in Japan and interim results expected in 2017. IONSYS was in-licensed from The Medicines Company and SymBio expects to launch IONSYS in 2019. SymBio plans to build its own salesforce to support rigosertib and IONSYS.

INDUSTRY OUTLOOK

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. Building its own commercial infrastructure in the future should help establish SymBio more firmly as a partner of choice in Asia-Pacific. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operating leverage.

Y/E Dec	Revenue (¥m)	EBITDA (¥m)	PBT (¥m)	EPS (¥)	P/E (x)	P/CF (x)
2014	1955.0	(1134.0)	(1116.0)	(36.39)	N/A	N/A
2015	1933.0	(2641.0)	(2640.0)	(81.61)	N/A	N/A
2016e	1951.0	(2725.0)	(2733.0)	(84.51)	N/A	N/A
2017e	2290.0	(3295.0)	(3326.0)	(102.80)	N/A	N/A

Sector: Pharma & healthcare

Price: €5.86
Market cap: €38m
Market: Euronext Paris

Share price graph (€)



Company description

Theracision, based in southern Paris, sells a high-precision, high-intensity ultrasound system (EchoPulse) in Europe and Asia for non-invasive treatment of benign breast and thyroid growths. A US clinical programme is underway. A single-use consumable is required per treatment.

Price performance

%	1m	3m	12m
Actual	(2.3)	(19.0)	(29.8)
Relative*	(5.5)	(22.0)	(27.6)

* % Relative to local index

Analyst

Dr John Savin

Theracision (ALTHE)

INVESTMENT SUMMARY

Theracision's H116 update shows two EchoPulse ultrasound devices sold and three leased, with momentum building in consumable EPack sales for thyroid treatments. This gave H1 revenues of €463k. Our 2016 revenue target has been adjusted from €5.9m to €4.6m based on 20 EchoPulse sales. Cash on 30 June 2016 was €2m. A rights issue for €9.6 million gross was completed in August. The net proceeds might be €9.15m giving cash till at least mid 2017. Following the capital increase, Theracision's issued capital is 6,441,029 shares. H1 results are due on 18 October.

INDUSTRY OUTLOOK


A new study from Tübingen University in FA found that after 12 months 24/27 of patients were without residual vital BFA tissue. This could be the basis of a breast cancer indication; there are no cancer trials so far. The FDA has agreed a de novo 510(k) regulatory track and granted an IDE to start a 100 patient US fibroadenoma trial. US sales might start from H2 2019.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.8	(4.7)	(4.8)	(122.1)	N/A	N/A
2015	1.6	(6.9)	(7.0)	(140.4)	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: 18.5p
Market cap: £141m
Market: AIM

Share price graph (p)



Company description

Tissue Regenix is a UK-based company developing and commercialising medical devices for regeneration of soft tissue. It has three divisions including a US-based wound care subsidiary, orthopaedics/sports medicine and a cardiac division.

Price performance

%	1m	3m	12m
Actual	(5.1)	(8.6)	9.6
Relative*	(8.5)	(13.0)	0.4

* % Relative to local index

Analyst

Dr Linda Pomeroy

Tissue Regenix Group (TRX)

INVESTMENT SUMMARY

Tissue Regenix's (TRX) investment case is built on dCELL, a versatile regenerative medical technology, and its potential across wound care, orthopaedics and cardiac implants. We forecast that US wound care will be the initial driver of rapid sales growth, boosted by product launches from all three divisions. Recently the company has made progress on multiple fronts, including an increase in distribution reach for DermaPure, a dermal substitute for hard-to-heal chronic wounds and acute wounds in the US, and approval of SurgiPure XD, a porcine dermis Xenograft for use in hernia repair in the US. Meanwhile, the Orthopaedics division targets the significant medical need in meniscus and anterior cruciate ligament (ACL) repair with a potential CE mark submission and grant for OrthoPure XT end of 2016 and launch 2017 and OrthoPure XM grant and launch 2018. Further, TRX took a first step towards the commercialisation of human dCELL heart valves and DermaPure in the EU through a JV agreement with the German tissue bank in January. TRX held £13.5m in cash at H116.


INDUSTRY OUTLOOK

The adoption of biological, as opposed to standard treatments, is driven by the need for earlier intervention, cost savings and longer-term healing solutions.

Y/E Jan / Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2014	0.0	(6.5)	(6.3)	(0.88)	N/A	N/A
2015	0.1	(8.2)	(8.2)	(1.19)	N/A	N/A
2016e	2.4	(11.1)	(11.3)	(1.41)	N/A	N/A
2017e	6.4	(11.4)	(11.6)	(1.45)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$0.64
Market cap: US\$17m
Market: NASDAQ

Share price graph (US\$)

Company description

Tonix is an emerging specialty pharmaceutical focused on psychiatric and neurological disorders. TNX-102 SL for fibromyalgia is the most advanced programme, entering Ph III. It is also being developed for PTSD.

Price performance

%	1m	3m	12m
Actual	(13.2)	(69.3)	(91.0)
Relative*	(13.2)	(68.9)	(91.4)

* % Relative to local index

Analyst

Maxim Jacobs

Tonix Pharmaceuticals (TNXP)

INVESTMENT SUMMARY

Tonix is a company focused on the development of TNX-102 SL for post-traumatic stress disorder (PTSD). Data for its 237-patient, Phase II proof-of-concept trial in PTSD were announced in May and showed a statistically significant benefit to patients in the primary endpoint at the high dose (5.6mg). The company is currently planning to initiate a Phase III trial in military-related PTSD early next year with another in predominantly civilian PTSD to follow. Breakthrough Therapy Designation is possible which would allow for an expedited approval process and increased interaction with the FDA.

INDUSTRY OUTLOOK

Tonix is an emerging specialty pharmaceutical company focused on psychiatric and neurological disorders.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(27.7)	(27.6)	(277.0)	N/A	N/A
2015	0.0	(48.2)	(48.1)	(286.0)	N/A	N/A
2016e	0.0	(41.3)	(41.1)	(240.0)	N/A	N/A
2017e	0.0	(45.1)	(48.1)	(270.0)	N/A	N/A

Sector: Pharma & healthcare

Price: €3.11
Market cap: €120m
Market: Euronext Paris

Share price graph (€)

Company description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Price performance

%	1m	3m	12m
Actual	15.6	13.9	1.6
Relative*	11.8	9.8	4.8

* % Relative to local index

Analyst

Juan Pedro Serrate

Transgene (TNG)

INVESTMENT SUMMARY

Transgene is focused on advancing the clinical development of its cancer immunotherapy products (oncolytic virus Pexa-Vec and MUC1 cancer vaccine TG4010) in combination with immune checkpoint inhibitors (ICIs) and infectious disease programs (TG1050 for HBV and TG4001 for HPV). Discussions with partners are underway to start five Phase II trials, including TG4010+ICI in the 1st/2nd-line treatment of NSCLC and Pexa-Vec+ICI in the first-line treatment of liver cancer/other solid tumours. The first studies should start in mid-2016 with potential readouts by end-2017. Transgene and partner Sillajen are running a global 600-patient Phase III study in liver cancer. TG1050 for HBV is advancing through Phase I/Ib testing. In October 2016 it announced a collaboration agreement with Merck and Pfizer to evaluate TG4001 with Avelumab in HPV-positive Head & Neck Cancer patients in a Phase 1/2 Study. Last stated cash is €33.4m (30 June 2016).


INDUSTRY OUTLOOK

Immunotherapies are among the most promising class of products for cancer. Increased attention is now being paid to the use of combination therapy approaches to improve cancer response rates further.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	11.1	(35.5)	(38.9)	(103.25)	N/A	N/A
2015	9.6	(25.7)	(28.9)	(78.08)	N/A	N/A
2016e	6.1	(23.9)	(27.2)	(70.55)	N/A	N/A
2017e	7.8	(27.9)	(31.5)	(81.87)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.92
Market cap: €38m
Market: Euronext Paris

Share price graph (€)

Company description

TxCell is a pioneer in developing regulatory T-cell therapies against autoimmune and inflammatory disorders. The lead product in Crohn's disease is planned to start Phase IIb in 2018. A novel CAR Treg technology platform is in early development.

Price performance

%	1m	3m	12m
Actual	(15.4)	(28.3)	(54.6)
Relative*	(18.1)	(30.9)	(53.2)

* % Relative to local index

Analyst

Dr John Savin

TxCell (TXCL)

INVESTMENT SUMMARY

TxCell offers a fast developing and novel opportunity in the new field of T-regulatory-cells. The lead product, Ovasave, uses an ovalbumin (egg white) trigger to activate autologous regulatory T-cells to control Crohn's disease. CAR T-reg cells are being developed to control a variety of major autoimmune disorders. In August, TxCell received €1.1m in advance Tax credits and drew down €3m of convertible loans of which €300k have converted to shares. By the beginning of 2017, TxCell expects to receive a further €1m in advance tax credits and draw a further €2m in convertible loans. Operational cash use in 2016 is now guided at €12m, down from €15m.


INDUSTRY OUTLOOK

The planned Ovasave Phase IIb trial will now switch to a new, faster manufacturing process which will delay the start till 2018, formerly late 2016. The earlier, but more flexible CAR Treg platform is being developed with academic partners to address indications like lupus nephritis, bullous pemphigoid and perhaps multiple sclerosis.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	1.4	(8.7)	(8.7)	(82.6)	N/A	N/A
2015	1.6	(10.8)	(10.7)	(87.4)	N/A	N/A
2016e	0.0	(14.5)	(14.5)	(111.8)	N/A	N/A
2017e	0.0	(18.3)	(18.3)	(135.1)	N/A	N/A

Sector: Pharma & healthcare

Price: 653.0p
Market cap: £1611m
Market: LSE

Share price graph (p)

Company description

UDG is a leading international provider of services to healthcare manufacturers and pharmacies. It employs 8,300 staff and is present in 22 countries. Its three divisions are Ashfield Commercial & Medical Services, Supply Chain Services and Sharp Packaging Services.

Price performance

%	1m	3m	12m
Actual	3.1	11.1	34.8
Relative*	(0.5)	5.9	23.5

* % Relative to local index

Analyst

Lala Gregorek

UDG Healthcare (UDG)

INVESTMENT SUMMARY

UDG held a capital markets day on 27 September hosted by senior management across all divisions and regions. Ashfield is expected to contribute c 60% of UDG's profits in 2016. The UK is the most mature market with the highest outsourcing rates. The key focus is on the US, EU and Japan. Ashfield's current operating margin of 12% after 'pass-through' costs is seen gradually growing thanks to the positive mix effect. At Sharp, medium-term constant currency operating profit growth is guided at 10% pa. Market expansion in packaging is seen at 5-10%, while clinical services enjoy up to 10% growth. UDG recognises the need for both organic and M&A-led growth in clinical services in order to upscale the business and win larger pharma customers.

INDUSTRY OUTLOOK

We understand that the company considers 2.0x net debt-to-EBITDA as comfortable, suggesting that there is capacity to borrow in total up to €600m in addition to the recent M&A proceeds and cash on hand. If the company is unable to find attractive M&A targets within 12 months it may consider returning funds to shareholders.

Y/E Sep	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	764.0	98.0	46.0	23.2	32.2	19.4
2015	919.0	126.0	70.0	27.4	27.3	11.0
2016e	975.0	129.0	81.0	28.6	26.1	14.8
2017e	1020.0	135.0	100.0	31.1	24.0	14.4

Sector: Pharma & healthcare

Price: 39.5p
Market cap: £208m
Market: AIM

Share price graph (p)

Company description

Vernalis is a UK speciality pharma company with an FDA-approved, prescription-only cough cold treatment, Tuzistra XR; an FDA approved amoxicillin, Moxatag; and a late-stage US cough cold pipeline of four products.

Price performance

%	1m	3m	12m
Actual	(9.2)	(16.0)	(45.9)
Relative*	(12.4)	(20.0)	(50.4)

* % Relative to local index

Analyst

Lala Gregorek

Vernalis (VER)

INVESTMENT SUMMARY

Vernalis marked its transition into a commercial stage speciality pharma company with the September 2015 US launch of Tuzistra XR, the first product from its extended release prescription only cough cold pipeline. First year (FY16) Tuzistra XR net sales were £1.1m. £40m in new funds raised in May provides resources to invest in operational initiatives (pharmacy stocking and patient access) to support stronger sales growth into the 2016/17 cough cold season and beyond. Successful execution will lay important foundations for the launch of CCP-07 into the following season, subject to approval on or before its 20 April 2017 PDUFA date. NDA filing of the third the cough cold programme, CCP-08, is anticipated by year-end 2016.

INDUSTRY OUTLOOK

Generic IR liquid products dominate the US Rx cough cold market, reflecting difficulties in formulating ER liquids that satisfy current FDA regulations; Tuzistra XR meets these standards. Favourable pricing and reimbursement of the five cough cold products in development by Vernalis would value the addressable market at up to \$3.5bn.

Y/E Jun	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	19.9	(8.9)	(6.9)	(1.0)	N/A	N/A
2016	12.0	(23.9)	(16.2)	(3.4)	N/A	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: A\$1.25
Market cap: A\$300m
Market: ASX, OTC QX

Share price graph (A\$)

Company description

Viralytics is a biopharmaceutical company developing Cavatak oncolytic virotherapy to target late-stage melanoma and other solid tumour types. It is trialling Cavatak as a monotherapy and in combination with checkpoint inhibitors.

Price performance

%	1m	3m	12m
Actual	34.4	34.4	123.2
Relative*	32.1	35.6	115.6

* % Relative to local index

Analyst

Dr Dennis Hulme

Viralytics (VLA)

INVESTMENT SUMMARY

Viralytics is well-positioned to benefit from industry interest in oncolytic virotherapy. Nine of the first 17 (53%) patients with advanced melanoma experienced objective responses following treatment with Cavatak in combination with the immune checkpoint inhibitor Yervoy (ipilimumab), in the Phase Ib MITCI trial. This impressive preliminary response rate compares to response rates of 28% and 11% reported for Cavatak and Yervoy, respectively, as single agents in advanced melanoma. Other ongoing trials include the Phase I/II STORM study in multiple solid cancers and an open-label Phase Ib trial of Cavatak in combination with Keytruda (pembrolizumab) in late-stage melanoma. The Phase I/II CANON trial in superficial bladder cancer, showed evidence of tumour targeting and anticancer activity. Viralytics and Merck are collaborating on Keynote 200 (STORM Part B), a Phase Ib trial of Cavatak and Keytruda in advanced lung and bladder cancer. Cash at 30 June was A\$46m. We are currently updating our model for FY16 results.

INDUSTRY OUTLOOK


The emergence of targeted and immunotherapy agents in recent years is redefining the treatment paradigm in metastatic melanoma. The FDA approval of Amgen's Imlygic (T-vec) has made oncolytic virotherapy a commercial reality.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2014	2.5	(4.9)	(4.7)	(3.9)	N/A	N/A
2015	2.5	(6.0)	(5.5)	(3.0)	N/A	N/A
2016e	4.4	(10.2)	(9.9)	(4.7)	N/A	N/A
2017e	4.4	(10.2)	(9.4)	(4.0)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$4.92
Market cap: US\$127m
Market: NYSE MKT

Share price graph (US\$)



Company description

VolitionRx is a Belgium-based diagnostics company focused on developing blood-based cancer diagnostics based on its proprietary NuQ technology. Its lead program is in colorectal cancer, which may enter the European market in 2016.

Price performance

%	1m	3m	12m
Actual	(3.5)	49.1	6.3
Relative*	(3.5)	51.0	1.0

* % Relative to local index

Analyst

Maxim Jacobs

VolitionRx (VNRX)

INVESTMENT SUMMARY

VolitionRx's proprietary NuQ technology detects the level and structure of nucleosomes in the blood using one drop of blood serum. It is currently focused on colorectal cancer (CRC), a very large opportunity with around 225 million people eligible for screening (US/EU). The company recently announced its first product, the NuQ triage colorectal cancer test which will launch in certain European countries in early 2017. The company also announced that it is initiating a study with DKFZ, the German Cancer Research Center, to evaluate NuQ blood tests for the detection of pancreatic cancer. This follows two successful pilot studies using its biomarkers in pancreatic cancer. A US 510(k) approval and launch is expected in late 2017 or early 2018.

INDUSTRY OUTLOOK

The blood-based cancer screening market is in its nascent stages with great potential and serves an unmet medical need. Currently there are few, if any, non-invasive screening methods for the vast majority of cancers.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(5.9)	(8.4)	(62.08)	N/A	N/A
2015	0.0	(10.0)	(9.7)	(54.49)	N/A	N/A
2016e	0.0	(15.1)	(15.1)	(67.06)	N/A	N/A
2017e	1.4	(16.9)	(16.9)	(71.87)	N/A	N/A

Company coverage

Company	Note	Date published
4SC	Update; Update	15/08/2016; 06/10/2016
Abzena	Update; Update	28/07/2016; 14/09/2016
Achillion Pharmaceuticals	Update; Update	26/01/2016; 28/09/2016
Actinium Pharmaceuticals	Update; Update	09/02/2015; 18/03/2015
Adherium	Outlook; Update	20/04/2016; 06/10/2016
AFT Pharmaceuticals	QuickView; Outlook	21/12/2015; 31/05/2016
Akari Therapeutics	Update; Outlook	08/07/2016; 14/07/2016
Angle	Update; Update	27/05/2016; 01/08/2016
Athersys	Update; Update	19/04/2016; 30/06/2016
Atossa Genetics	Update; Flash	27/05/2016; 02/09/2016
Basilea Pharmaceuticals	Update; Update	30/08/2016; 16/09/2016
C4X Discovery	Flash; Flash	06/09/2016; 29/09/2016
Carmat	Update; Update	05/05/2016; 15/07/2016
Celyad	Update; Update	10/06/2016; 13/07/2016
Consort Medical	Update; Update	09/09/2016; 17/10/2016
Crossject	Initiation; Update	13/06/2016; 23/06/2016
e-Therapeutics	Outlook; Update	19/05/2016; 20/09/2016
Evotec	Outlook; Update	29/06/2016; 16/08/2016
Genedrive		
Gentice	Update; Update	07/06/2016; 28/06/2016
GW Pharmaceuticals	Outlook; Update	25/02/2016; 08/06/2016
Hutchison China Meditech	Outlook	31/05/2016
Hybrigenics	Update; Update	15/02/2016; 18/05/2016
Imperial Innovations	Update; Update	06/09/2016; 27/09/2016
Intec Pharma	Initiation	28/09/2016
International Stem Cell	Outlook; Update	16/05/2016; 02/08/2016
Kiadis Pharma	Outlook	15/09/2016
MagForce	Update	09/02/2015
Medigene	Update; Update	08/08/2016; 05/10/2016
Mesoblast	Outlook; Update	08/07/2016; 21/09/2016
Midatech	Update; Update	28/12/2015; 06/01/2016
Mologen	Outlook; Update	21/07/2016; 01/09/2016
MorphoSys	Update; Outlook	17/12/2015; 17/05/2016
Nanobiotix	Update; Outlook	01/02/2016; 31/05/2016
Neovacs	Update; Outlook	23/04/2016; 01/08/2016
NetScientific	Initiation; Outlook	13/06/2016; 26/08/2016
Newron Pharmaceuticals	Flash; Outlook	31/03/2016; 2/09/2016
Nexstim	Update; Update	27/07/2016; 28/09/2016
Onxeo	Update; Update	02/06/2016; 23/08/2016
Opexa Therapeutics	Update; Update	01/04/2016; 30/06/2016
Orexigen Therapeutics	Update; Update	12/04/2016; 19/08/2016

Orexo	Update; Update	10/08/2016; 07/10/2016
Oryzon Genomics	Update; Update	20/05/2016; 08/08/2016
Oxford BioMedica	Flash; Outlook	05/05/2015; 27/07/2015
Pacific Edge	Update; Outlook	07/12/2015; 24/06/2016
Paion	Update; Update	17/05/2016; 05/07/2016
PDL BioPharma	Update; Update	15/07/2016; 11/08/2016
PharmaMar	Update; Update	05/05/2016; 27/09/2016
Photocure	Update; Outlook	25/05/2016; 21/09/2016
Pixium Vision	Update; Update	15/07/2016; 27/07/2016
Prescient Therapeutics	Update; Update	28/09/2015; 03/03/2016
Prima BioMed	Outlook; Outlook	27/07/2016; 02/08/2016
Probiodrug	Outlook; Update	06/09/2016; 13/09/2016
Regeneus	Update; Update	19/05/2016; 14/09/2016
ReNeuron Group	Outlook; Update	27/07/2016; 05/08/2016
Selvita	Update; Update	22/08/2016; 14/10/2016
Silence Therapeutics	Initiation	25/07/2016
StemCells	Update; Update	08/06/2016; 05/02/2016
Stratec Biomedical	Update; Update	04/04/2016; 15/06/2016
Sunesis Pharmaceuticals	Update; Update	03/08/2016; 16/09/2016
Sygnis Pharma	Update; Update	19/05/2016; 19/09/2016
SymBio Pharmaceuticals	Update; Update	07/12/2015; 23/03/2016
Theraclion	Initiation; Update	26/02/2016; 25 /07/2016
Tissue Regenix	Outlook; Update	28/07/2016; 15/09/2016
Tonix Pharmaceuticals	Update; Update	25/05/2016; 03/10/2016
Transgene	Update; Update	13/04/2016; 21/09/2016
TxCell	Outlook; Update	31/05/2016; 24/06/2016
UDG Healthcare	Update; Update	21/07/2016; 10/10/2016
Vernalis	Flash; Update	28/04/2016; 25/05/2016
Viralytics	Update; Update	05/05/2016; 16/06/2016
VolitionRx	Update; Outlook	01/04/2016; 23/09/2016

Investment companies

BB Biotech AG	Investment trust review	11/03/2015; 09/02/2016
Biotech Growth Trust (The)	Investment trust review	18/02/2015; 15/12/2015
International Biotechnology Trust	Investment trust review	03/03/2015; 11/12/2015

QuickViews

To view the following QuickViews see the [healthcare](#) sector profile page on our website.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance.

Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2016. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
245 Park Avenue, 39th Floor
10167, New York
United States

Sydney +61 (0)2 9258 1161
Level 25, Aurora Place
88 Phillip St, Sydney
NSW 2000, Australia

Wellington +64 (0)4 8948 555
Level 15, 171 Featherston St
Wellington 6011
New Zealand

Edison Investment Research Limited is registered in England. Registered office: 280 High Holborn, London, WC1V 7EE. Company number 4794244. www.edisongroup.com